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Abstract
Background
According to the latest revised National Institute of Neurological and Communicative Disorders and Stroke and the
Alzheimer's Disease and Related Disorders Association (now known as the Alzheimer's Association) (NINCDS-ADRDA)
diagnostic criteria for Alzheimer's disease dementia of the National Institute on Aging and Alzheimer Association, the
confidence in diagnosing mild cognitive impairment (MCI) due to Alzheimer's disease dementia is raised with the application
of biomarkers based on measures in the cerebrospinal fluid (CSF) or imaging. These tests, added to core clinical criteria,
might increase the sensitivity or specificity of a testing strategy. However, the accuracy of biomarkers in the diagnosis of
Alzheimer’s disease dementia and other dementias has not yet been systematically evaluated. A formal systematic
evaluation of sensitivity, specificity, and other properties of plasma and CSF amyloid beta (Aß) biomarkers was performed.
Objectives
To determine the accuracy of plasma and CSF Aß levels for detecting those patients with MCI who would convert to
Alzheimer's disease dementia or other forms of dementia over time.
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Search methods
The most recent search for this review was performed on 3 December 2012. We searched MEDLINE (OvidSP), EMBASE
(OvidSP), BIOSIS Previews (ISI Web of Knowledge), Web of Science and Conference Proceedings (ISI Web of Knowledge),
PsycINFO (OvidSP), and LILACS (BIREME). We also requested a search of the Cochrane Register of Diagnostic Test
Accuracy Studies (managed by the Cochrane Renal Group).
No language or date restrictions were applied to the electronic searches and methodological filters were not used so as to
maximise sensitivity.
Selection criteria
We selected those studies that had prospectively well defined cohorts with any accepted definition of cognitive decline, but
no dementia, with baseline CSF or plasma Aß levels, or both, documented at or around the time the above diagnoses were
made. We also included studies which looked at data from those cohorts retrospectively, and which contained sufficient data
to construct two by two tables expressing plasma and CSF Aß biomarker results by disease status. Moreover, studies were
only selected if they applied a reference standard for Alzheimer's dementia diagnosis, for example the NINCDS-ADRDA or
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria.
Data collection and analysis
We screened all titles generated by the electronic database searches. Two review authors independently assessed the
abstracts of all potentially relevant studies. We assessed the identified full papers for eligibility and extracted data to create
standard two by two tables. Two independent assessors performed quality assessment using the QUADAS-2 tool. Where
data allowed, we derived estimates of sensitivity at fixed values of specificity from the model we fitted to produce the
summary receiver operating characteristic (ROC) curve.
Main results
Alzheimer's disease dementia was evaluated in 14 studies using CSF Aß42. Of the 1349 participants included in the meta-
analysis, 436 developed Alzheimer’s dementia. Individual study estimates of sensitivity were between 36% and 100% while
the specificities were between 29% and 91%. Because of the variation in assay thresholds, we did not estimate summary
sensitivity and specificity. However, we derived estimates of sensitivity at fixed values of specificity from the model we fitted
to produce the summary ROC curve. At the median specificity of 64%, the sensitivity was 81% (95% CI 72 to 87). This
equated to a positive likelihood ratio (LR+) of 2.22 (95% CI 2.00 to 2.47) and a negative likelihood ratio (LR–) of 0.31 (95% CI
0.21 to 0.48).
The accuracy of CSF Aß42 for all forms of dementia was evaluated in four studies. Of the 464 participants examined, 188
developed a form of dementia (Alzheimer’s disease and other forms of dementia).The thresholds used were between 209
mg/ml and 512 ng/ml. The sensitivities were between 56% and 75% while the specificities were between 47% and 76%. At
the median specificity of 75%, the sensitivity was estimated to be 63% (95% CI 22 to 91) from the meta-analytic model. This
equated to a LR+ of 2.51 (95% CI 1.30 to 4.86) and a LR– of 0.50 (95% CI 0.16 to 1.51).
The accuracy of CSF Aß42 for non-Alzheimer's disease dementia was evaluated in three studies. Of the 385 participants
examined, 61 developed non-Alzheimer's disease dementia. Since there were very few studies and considerable variation
between studies, the results were not meta-analysed. The sensitivities were between 8% and 63% while the specificities
were between 35% and 67%.
Only one study examined the accuracy of plasma Aß42 and the plasma Aß42/Aß40 ratio for Alzheimer's disease dementia.
The sensitivity of 86% (95% CI 81 to 90) was the same for both tests while the specificities were 50% (95% CI 44 to 55)
and 70% (95% CI 64 to 75) for plasma Aß42 and the plasma Aß42/Aß40 ratio respectively. Of the 565 participants examined,
245 developed Alzheimer’s dementia and 87 non-Alzheimer's disease dementia.
There was substantial heterogeneity between studies. The accuracy of Aß42 for the diagnosis of Alzheimer's disease
dementia did not differ significantly (P = 0.8) between studies that pre-specified the threshold for determining test positivity (n
= 6) and those that only determined the threshold at follow-up (n = 8). One study excluded a sample of MCI non-Alzheimer's
disease dementia converters from their analysis. In sensitivity analyses, the exclusion of this study had no impact on our
findings. The exclusion of eight studies (950 patients) that were considered at high (n = 3) or unclear (n = 5) risk of bias for
the patient selection domain also made no difference to our findings.
Authors' conclusions
The proposed diagnostic criteria for prodromal dementia and MCI due to Alzheimer's disease, although still being debated,
would be fulfilled where there is both core clinical and cognitive criteria and a single biomarker abnormality. From our review,
the measure of abnormally low CSF Aß levels has very little diagnostic benefit with likelihood ratios suggesting only marginal
clinical utility. The quality of reports was also poor, and thresholds and length of follow-up were inconsistent. We conclude
that when applied to a population of patients with MCI, CSF Aß levels cannot be recommended as an accurate test for
Alzheimer's disease.
Plain language summary
Proteins in blood and cerebrospinal fluids for early prediction of developing Alzheimer’s disease or other
dementia in people with cognitive problems
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The numbers of people with dementia and other cognitive problems are increasing globally. A diagnosis of the pre-
dementia phase of disease is recommended but there is no agreement on the best approach. A range of tests have been
developed which healthcare professionals can use to assess people with poor memory or cognitive impairment. In this
review, however, we have found that measuring protein in cerebrospinal fluid (CSF amyloid beta (Aβ40) or CSF Aβ42), as a
single test, lacks the accuracy to identify those patients with mild cognitive impairment who would develop Alzheimer's
disease dementia or other forms of dementia.
Background 
Alzheimer’s disease is an incurable, progressive, neurodegenerative condition which accounts for over 50% of
dementias, afflicting 5% of men and 6% of women over 60 years old worldwide (World Health Organization 2010). As
age is the principal risk factor, the general ageing of the global population, despite some suggestions that dementia
incidence is falling, means that the total number of people suffering from Alzheimer's dementia is likely to still be
increasing. The prevalence increases exponentially with age as Alzheimer's dementia affects < 1% of people aged 60 to
64 years old and 24% to 33% of those aged over 85 years (Ferri 2005).
It is important to distinguish Alzheimer's disease (which is the underlying pathology) from Alzheimer's dementia, which is the
final stage of a clinical syndrome that develops as a result of the pathology. The diagnosis of pre-dementia Alzheimer's
disease is currently being debated and the best nosology to define this stage of illness lacks consensus, especially with
regards to the use of various terms (for example prodromal dementia) in clinical practice. It is also important to be able to
distinguish between the various subtypes of dementia as early as possible in the course of illness to maximise the impact of
treatment and risk modification.
The target condition being diagnosed by the testing of cerebrospinal fluid (CSF) and plasma for amyloid beta (Aß)
40 or 42 and the 40/42 ratio is Alzheimer's disease both as a distinct entity from normal ageing as well as from
other subtypes of dementia (for example vascular dementia, Lewy body dementia and frontotemporal dementias).
In this review we aimed to determine whether CSF or plasma Aß levels were diagnostic of Alzheimer's disease in
people with cognitive impairment but no dementia. Subsequent reviews will explore the accuracy of this test to
discriminate between subtypes of dementia (Kokkinou 2014).
The first complaints that people make (either to their general practitioner (GP) or to family) are often regarding
subjective cognitive complaints such as memory lapses or getting lost. This may lead to a diagnosis of mild cognitive
impairment (MCI) being made if formal testing reveals objective evidence of cognitive impairment. In some people, this
will progress to Alzheimer's dementia, though currently we are unable to accurately predict those who will progress.
This has led to the development of numerous research programmes seeking to define clinical, cognitive and biomarker
tests that can identify those with MCI who will develop dementia. The presence of Alzheimer's disease, which may be
indexed by low levels of CSF or plasma Aß, in patients with early cognitive complaints is thereby considered to be a
very strong risk factor for developing Alzheimer's dementia in the future. Therefore, the presence of Alzheimer's
disease within patients with MCI is proposed as being a diagnostic test for the delayed verification of Alzheimer's
disease dementia (Davis 2013).
Alzheimer's pathology is associated with a central amyloidosis and for many years the amyloid cascade hypothesis (Hardy
1992) has been used to describe the disruption of a probably normal cerebral process which is associated with
ageing and how this disruption can lead to Alzheimer's disease. The model describes a pathway by which Aß
monomers are produced, aggregate into oligomers and then are sequestered and potentially inactivated into the
characteristic extracellular amyloid plaques. This may explain why on neuroimaging some cognitively ‘normal’
individuals have amyloid plaques after the age of 65 years (Aizenstein 2008). In Alzheimer's disease, however, the
equilibrium of this system is biased to pathological, away from a physiological function, and an increased conversion to the
Aß oligomers from the ‘inert’ monomers results in a toxic pool of soluble amyloid species which are central to the
neurotoxicity of Alzheimer's disease. The amount of oligomeric Aß is too great to be sequestered into plaque and thereby
remains present in the extracellular space to exert its toxic effects. As a consequence of neuronal disruption from these
oligomeric species, intracellular cascades may lead to the hyperphosphorylation of tau, compromising the cytoskeletal
protein tubulin with the development of neuro-fibrillary tangles (NFTs). Toxic oligomers may also compromise synaptic
activity leading in part to the clinical symptoms of MCI and eventually Alzheimer's disease dementia. There is also an
associated inflammatory response from glial cells causing oxidative stress, synaptotoxicity and (via excess glutamate
release) neurotoxicity. At the latter stages of disease progression the senile plaques are believed to also be pro-inflammatory
and thereby stimulate a further neurotoxic inflammatory response.
The amyloid hypothesis has yet to be decisively proven however (Shankar 2008) and one conflicting argument
states that the increased production of Aß in Alzheimer's disease is a protective mechanism, due to its potent
antioxidant ability, to counter a primary upstream effect, with mitochondrial dysfunction being heavily implicated (Castellani
2004). Moreover, the amyloid hypothesis has been questioned in light of recent studies and drug trials which have
indicated no impact on the clinical course of disease after significant reduction in post-mortem cerebral amyloid
following active immunisation (Holmes 2008).
There are two main pathological isoforms of Aß, defined by their amino acid length: 40 and 42. Aß42 has a greater
capacity to form oligomers and thereafter fibrils (the main constituent of amyloid plaques) and therefore has a higher
neurotoxicity than its shorter counterpart Aß40. Successive ß- and ƴ-secretase cleavage of the ubiquitous amyloid
precursor protein (APP) is responsible for Aß42 production. The ɑ-secretase cleavage of APP does not form either of these
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amyloid proteins but produces a much more soluble shorter moiety, Aß17, and its action is relatively suppressed in
Alzheimer's disease. Despite the increased production of Aß42 in Alzheimer's disease, the trafficking of Aß42 into plaques
may in fact lead to an observable lowering of the CSF and plasma levels of Aß42 with maintenance of the smaller, more
soluble species in Alzheimer's disease compared to age-matched controls. Therefore studies have shown that consistently
there is a lowering of CSF levels of Aß42 in Alzheimer's disease dementia compared with controls, which may be indicative
of extant central Aß pathology. Hypothetically, as the Aß42 levels decrease to a greater degree than the Aß40 levels, it
follows that the ratio of Aß42:Aß40 will decrease, which may prove to be a more accurate test for Alzheimer's disease
pathology than the absolute values of each protein in plasma or CSF.
It is worth noting that the Aß found in plasma is likely to have emanated from the alpha granules of platelets, where
APP is also found in abundance, and therefore may be less closely related to the Alzheimer's disease central
pathology. Little concurrence has been found between plasma and CSF Aß levels (Mehta 2001), therefore CSF Aß assays
may prove to be a more accurate reflection of central amyloid pathology associated with Alzheimer's disease. However, as
plasma is a much more accessible bodily fluid than CSF the accuracy of plasma Aß in diagnosing Alzheimer's disease
pathology merits review.
There have been numerous attempts to clinically define the pre-dementia phase of neurodegenerative disease. MCI is a
heterogeneous condition which has been defined, using clinical criteria, by several authors, for example Petersen 1999.
There have been over a dozen different definitions used to describe cognitive impairment that exceeds in extent
and is somehow qualitatively different from normal ageing. Whilst remaining attentive to the widely differing
prognostic implications of the differing terms, in this review the term MCI will be used to collectively describe the 16
conditions included in the research by Matthews 2008 (Matthews 2008). This leads to the proposal that from within these
populations additional tests may help support the notion that there is central pathology that will mediate (over time)
progression to one of the dementia syndromes. Knowing that a person with MCI has Alzheimer's disease as the cause of
their symptoms would allow for the targeting of (future) disease modifying therapies, risk modifying strategies as well as
psychosocial management.
There is currently no pre-mortem gold standard test for Alzheimer's disease pathology. The observation that a patient with
MCI, when followed carefully over time, develops Alzheimer's disease dementia can be taken (for the purposes of this
review) that they had Alzheimer's disease pathology at baseline (that is when diagnosed with MCI) and it was this
Alzheimer's pathology that caused the symptoms observed in MCI. However, since vascular events and Lewy body
pathology may not be independent of amyloid pathology, it is also important to examine whether the index test predicts all
causes of dementia and whether the accuracy in predicting these outcomes is different from the accuracy of predicting
Alzheimer's disease dementia.
Inevitably this means that studies exploring the diagnostic accuracy of a test in MCI for Alzheimer's disease pathology will
have a long time interval between the diagnostic test and the reference standard being applied (that is conversion to
Alzheimer's disease dementia). However, as the course of this illness cannot be interrupted or affected by any therapeutic
intervention, this is not as problematic as it would be in other conditions where interventions have an effect on the course of
disease. Accordingly, studies must be long enough to allow 'conversion' from MCI to Alzheimer's disease dementia to occur
and must use standardised criteria both to define the baseline population (MCI) and the conversion to Alzheimer's disease
dementia.
In essence this review aims to understand the diagnostic test accuracy of Aß40 or Aß42, or their ratio, in CSF or plasma in
patients with any of the described forms of MCI to identify them as having Alzheimer's disease pathology.
Target condition being diagnosed
Alzheimer's disease dementia1.
Other forms of dementia2.
Index test(s)
Studies that assessed the accuracy of plasma or CSF measurements of:
Aß42, or
Aß40, or
Aß42 to Aß40 ratio.
Aß is measured in ng.l-1 or pg.ml-1, which generate the same values.
The assays most commonly used are the conventional Innogenetics INNOTEST® beta-amyloid1-42 kit or the multiplexing
INNO-BIA AlzBio3 for CSF, or INNO-BIA plasma Aß forms for plasma.
Clinical Pathway 
Dementia develops over a trajectory of several years. There is a presumed period when people are asymptomatic, and when
pathology is accumulating. Individuals or their relatives may notice subtle impairments of recent memory. Gradually more
cognitive domains become involved and difficulty planning complex tasks becomes increasingly apparent. In the UK, people
often present to their GP when they or a family member or friend note memory deficits. The GP will potentially refer them to a
memory clinic after taking a history of the problem and conducting a brief assessment of cognitive function. However, many
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people with dementia do not present to their GP for several years after the first onset of symptoms and will follow a different
pathway to diagnosis, for example being identified during an admission to a general hospital for a physical illness.
Access to diagnostic assessment pathways may vary in other healthcare settings and diagnoses may be made by a variety
of specialists including neurologists and geriatricians, who may rely to a greater or lesser degree on tests to assist with the
diagnosis. In recent years there have been attempts across the world to identify dementia at the earliest stage, with an
emphasis on the GP being vigilant in observing their patients for cognitive decline and then making referrals to specialist
services. Accordingly, there is a growing interest in the accuracy of cognitive tests to support a referral and then of
biomarkers (such as in imaging and in plasma or CSF) applied in specialist centres.
Alternative test(s)
We did not include alternative tests in this review because there are currently no standard practice tests available for the
diagnosis of dementia. 
This review is one of a series of diagnostic test accuracy reviews of biomarkers and scales being conducted by the Cochrane
Dementia and Cognitive Improvement Group (CDCIG):
CSF (cerebrospinal fluid analysis of tau and tau/Aß ratio);
sMRI (structural magnetic resonance imaging);
18F-2-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG-PET);
positron emission tomography Pittsburg Compound-C (11C-PIB-PET);
neuropsychological tests (Mini-Mental State Examination (MMSE); Mini-Cog; Montreal Cognitive Assessment (MoCA));
informant interviews (IQCODE; AD8);
apolipoprotein Ɛ4 (APOEƐ4);
regional cerebral blood flow single photon emission computerised tomography (rCBF SPECT).
Although we are conducting reviews on individual tests compared to a reference standard, we plan to compare the results
from the reviews in an overview.
Rationale
The two recently proposed diagnostic criteria for Alzheimer’s disease referred to MCI due to Alzheimer’s disease
pathology and the prodromal (pre-dementia phase) of Alzheimer's disease pathology (Albert 2011; Dubois 2010) and
incorporate biomarkers based on imaging or CSF measures within the diagnostic rubric. These tests are core to the criteria,
assuming they will improve the specificity of the traditional solely clinical criteria. It is crucial that each of these biomarkers is
assessed for their diagnostic accuracy before they are adopted as routine tests in clinical practice. It is worth noting that in
each of these criteria a single abnormality in any of the proposed biomarker or imaging tests is considered sufficient to make
a diagnosis of prodromal Alzheimer’s disease dementia.
Underpinning the new criteria is the assumption that if Alzheimer’s disease pathology can be diagnosed at an earlier,
pre-dementia stage, this could open critical windows for interventions that will have a greater likelihood of success in
affecting disease pathways and thereby improving clinical symptoms. Earlier, accurate diagnosis will also help people
with pre-dementia cognitive impairment and their families and potential carers make timely plans for the future.
Coupled with appropriate contingency planning, proper recognition of the disease may also help to prevent
inappropriate and potentially harmful admissions to hospital or institutional care (Bourne 2007). In addition, the accurate
early identification of a dementia syndrome may improve opportunities for the use of newly evolving interventions designed to
delay or prevent progression to more debilitating stages of dementia. 
Objectives 
To determine the accuracy of plasma and CSF Aß levels in identifying those participants with MCI at baseline who will
convert to Alzheimer’s disease dementia or other forms of dementia over time.
Secondary objectives
To determine the nature, extent and impact of heterogeneity on the diagnostic accuracy of plasma and CSF Aß levels.
Methods 
Criteria for considering studies for this review
Types of studies 
We included all studies that had prospectively well defined cohorts with any accepted definition of cognitive decline but no
dementia with baseline CSF or plasma Aß levels, or both, documented at or around the time that the above diagnoses were
made. We also included studies which looked at data from those cohorts retrospectively, and contained sufficient data to
construct 2 × 2 tables expressing plasma and CSF Aß biomarker results by disease status. The results in those that
progressed to clinical Alzheimer's dementia were compared to those who did not progress, improved or developed another
dementia.
We excluded any studies which potentially overlapped patient data and recorded them as multiple publications. We also
excluded review papers.
Participants
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We included participants who were diagnosed with a cognitive decline but with no dementia condition at baseline.
The cognitive decline but no dementia group is defined as patients who have been diagnosed using any of the
Petersen criteria, or Clinical Dementia Rating (CDR) = 0.5, or any of the 16 definitions included by Matthews (Matthews
2008).
We excluded those patients or populations with cognitive decline no dementia possibly caused by:
current or a history of alcohol or drug abuse;
central nervous system (CNS) trauma (e.g. subdural haematoma), tumour or infection;
other neurological conditions e.g. Parkinson’s or Huntingdon’s diseases;
any other dementia co-morbidity e.g. frontotemporal or vascular dementias.
We excluded studies that included patients with psychiatric, neurological, metabolic, immunological, hormonal or
cerebrovascular disorders, or patients likely to have a genetic cause for their dementia (for example familial autosomal
dominant Alzheimer’s disease or frontotemporal dementia, cerebral autosomal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy, or Huntington’s disease).
If participants were involved in disease modifying clinical trials we excluded them from the analysis.
Patients with a family history of Alzheimer's disease dementia may be more readily diagnosed with MCI and therefore there
can be spectrum bias with these participants. On this basis we examined separately those studies which included those with
a known genetic predisposition.
Similarly, early onset Alzheimer's disease dementia, defined as a diagnosis under the age of 50 years, is likely to
indicate a different aetiopathogenesis from late onset Alzheimer's disease dementia (including autosomally inherited
mutation in the presenilin 1 and 2 genes, or the amyloid precursor protein (Filley 2007)). We excluded studies which included
patients below the age of 50 years.
With regard to duration of follow-up, Bruscoli 2004 indicated that an annual average of 10% of MCI patients become
demented and therefore cohort studies would ideally have a minimum follow-up time of 24 months. This provides a
conversion rate to Alzheimer's disease dementia of approximately 19% and gives sufficient time for clinicians to diagnose a
cause of MCI. Shorter durations of follow-up may yield low conversion rates.
Index tests
Studies that assessed the accuracy of plasma or CSF measurements of:
Aß42, or Aß40, or the ratio Aß42/Aß40 were included.
There are currently no generally accepted standards for the plasma or CSF Aß test threshold, and therefore it was not
possible to pre-specify what constituted a positive or negative result. The thresholds that we used in this review were those
generated and presented within each included study. It should be noted that where Aß42 and Aß40 data were presented
separately, rather than as a ratio, then both tests would be analysed separately.
Measure of index test: Aß level in plasma or CSF, or both (ng.l-1 or pg.ml-1).
The assays most commonly used are conventional Innogenetics INNOTEST beta-amyloid1-42 kit or the multiplexing INNO-
BIA AlzBio3 for CSF, or INNO-BIA plasma Aß forms for plasma.
We did not include a comparator test because there are currently no standard practice tests available for the diagnosis of
dementia.
Target conditions
There were two target conditions in this review:
Alzheimer’s disease dementia (conversion from cognitive decline no dementia to Alzheimer’s disease dementia);1.
any other forms of dementia (conversion from cognitive decline no dementia to other (non-Alzheimer's) forms of2.
dementia);
any dementia (conversion from cognitive decline no dementia to any form of dementia).3.
Reference standards
The gold standard for Alzheimer's disease dementia is a post-mortem. There is no ‘gold-standard’ ante-mortem
diagnostic test for Alzheimer's disease dementia. Therefore, the reference standard in this review was conversion
from MCI to Alzheimer's disease dementia based on the National Institute for National Institute of Neurological and
Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)
criteria (McKhann 1984) to define ‘probable’ Alzheimer's disease.
The NINCDS-ADRDA criteria define three ante-mortem groups: probable, possible and unlikely Alzheimer's disease
dementia, based on evaluation of eight cognitive domains including memory and language.
The post-consensus (on those cases in which there is a disagreement) specificity of the NINCDS-ADRDA criteria is
0.84 and its sensitivity is 0.83 (Blacker 1994) against post-mortem diagnosis. Exploring the impact of using different post-
mortem definitions of Alzheimer's disease, Nagy 1998 showed that the sensitivity of ‘possible’ and ‘probable’ dementia
of the Alzheimer’s type according to NINCDS-ADRDA criteria is 91% to 98% compared to the post-mortem
Khachaturian criteria, Tierney A3 criteria and the CERAD protocol at autopsy. Studies using Diagnostic and Statistical
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Manual of Mental Disorders criteria (DSM) (DSMIII 1987; DSMIV 1994) or International Statistical Classification of
Diseases and Related Health Problems (ICD) criteria (World Health Organization 2010) exclusively to diagnose Alzheimer's
disease dementia were also considered though the criteria would be entered as a covariate to assess their impact on results.
For Lewy body dementia as an outcome the reference standard is the McKeith criteria (McKeith 1996); for
frontotemporal dementia, the Lund Criteria (Lund 1994); and for vascular dementia the NINDS AIREN criteria (Roman 1993).
Search methods for identification of studies 
Electronic searches 
The most recent search for this review was performed on 3 December 2012. We searched MEDLINE (OvidSP), EMBASE
(OvidSP), BIOSIS Previews (ISI Web of Knowledge), Web of Science and Conference Proceedings (ISI Web of Knowledge),
PsycINFO (OvidSP), and LILACS (BIREME). See Appendix 1 for details of the sources searched, the search strategies
used, and the number of hits that were retrieved.
We also requested a search of the Cochrane Register of Diagnostic Test Accuracy Studies (managed by the Cochrane
Renal Group).
We did not apply any language or date restrictions to the electronic searches; methodological filters were not used so as to
maximise sensitivity.
Searching other resources 
We checked the reference lists of all relevant studies for additional studies.
We also conducted searches in the MEDION database (Meta-analyses van Diagnostisch Onderzoek) at
www.mediondatabase.nl, Database of Abstracts of Reviews of Effects (DARE) at
www.york.ac.uk/inst/crd/crddatabases.htm#DARE, Health Technology Assessments Database (HTA Database) at
www.york.ac.uk/inst/crd/crddatabases.htm#HTA, and Aggressive Research Intelligence Facility (ARIF) database at
www.arif.bham.ac.uk for other related systematic diagnostic accuracy reviews; we searched for systematic reviews of
diagnostic studies from the International Federation of Clinical Chemistry and Laboratory Medicine Committee for Evidence-
based Laboratory Medicine database (C-EBLM). We checked reference lists of any relevant systematic reviews for additional
studies.
Data collection and analysis 
Selection of studies 
We selected studies initially from title and abstract screening by the review authors. We excluded articles on animal studies
at this stage. We then obtained the full text for each potentially eligible study. We independently assessed these papers
against the inclusion criteria for inclusion or exclusion. We resolved disagreements by discussion with a third author.
Data extraction and management
We extracted data to a study specific proforma which included the following.
Author, year of publication and journal.
The index test and assay type used (thresholds used to define positive and negative tests).
The criteria used for clinical definition for the baseline population.
Baseline demographics of the study population (age, gender, apolipoprotein E (ApoE) status, MMSE and clinical setting).
The duration of follow-up (mean, minimum, maximum and median).
The proportion of patients developing the outcome of interest (Alzheimer's dementia using NINCDS-ADRDA criteria) as
well as other dementias where standard criteria were used.
The sensitivity and specificity of the index test in defining Alzheimer's dementia was used to back-translate into a 2 x 2
table.
Other data relevant for creating 2 x 2 tables (TP = true test positive; FP = false test positive; FN = false test negative; TN =
true test negative) e.g. a number of 'abnormal' and 'normal' tests and at baseline; a number of disease 'presence' and
disease 'absence' at follow-up, as well as through scrutiny of scatter plots.
We piloted the proforma against two primary diagnostic studies (Bjerke 2009; Hampel 2004) and amended it as necessary.
We extracted data independently with disagreements then resolved by a third author.
Assessment of methodological quality
One review author and an independent assessor performed methodological quality assessments of each study using
the QUADAS-2 tool (Whiting 2011) as recommended by the Cochrane Collaboration.
The tool is made up of four domains: patient selection, index test, reference standard
and patient flow. Each domain is assessed in terms of risk of bias, with the first three
domains also considered in terms of applicability concerns (http://www.bris.ac.uk/quadas/quadas-2 Appendix 2). The
components of each of these domains and a rubric which details how judgments concerning risk of bias are made are
detailed in Appendix 3. Certain key areas important for this review regarding quality assessment were participant selection,
blinding and missing data.
Statistical analysis and data synthesis
We performed separate analyses for each test and for each form of dementia (Alzheimer's disease dementia, non-
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Alzheimer's disease dementia, and all forms of dementia). The disease negatives in each of these analyses were formed by
all participants who did not develop the disease of interest. For example, where Alzheimer's disease dementia was the
outcome, a participant developing another form of dementia would be in the disease negative group. We conducted
exploratory analyses by plotting estimates of sensitivity and specificity from each study on forest plots and in receiver
operating characteristic (ROC) space. To summarise test accuracy data across studies, we fitted hierarchical summary
receiver operating characteristic (HSROC) models using the NLMIXED procedure in the SAS software package (version 9.2;
SAS Institute, Cary, NC). The HSROC model accounts for between study variability through the inclusion of random effects
that allow for heterogeneity in threshold and accuracy. Studies with different thresholds can be included (one threshold per
study) in the HSROC model for the estimation of a summary ROC curve. A summary point can be identified on the summary
ROC curve but summary estimates of sensitivity and specificity only have a clinically meaningful interpretation at a specific
threshold. Therefore, in analyses where inclusion of studies was unrestricted by threshold, we used HSROC model
parameters to derive sensitivities, with 95% confidence intervals, at median, lower and upper quartile values of the
specificities from the included studies. When there were few studies and it was not possible to fit the complete HSROC
model, we simplified the model by assuming a symmetrical summary ROC curve or fixed-effect estimates, or both. In
additional analyses, we planned to restrict analyses to only those studies that reported data at a common threshold if there
were a sufficient number of studies.
Investigations of heterogeneity
The main sources of heterogeneity considered a priori were:
differences in test thresholds;1.
which proprietary laboratory tests were used to undertake the CSF and plasma analyses;2.
duration of follow-up: we planned to perform a subgroup analysis of short (< 2 years) and longer (2 or more years)3.
duration of follow-up;
criteria used for definition of cognitive impairment and dementia;4.
age of participants.5.
The HSROC model can be extended to include covariates to assess whether threshold, accuracy, or the shape of the
summary ROC curve varies with patient or study characteristics. Where possible, we investigated the effect of each potential
source of heterogeneity by using covariates to estimate differences in both the accuracy and threshold parameters, but the
underlying shape of the summary ROC curve was assumed to be constant. This assumption was necessary due to the
limited number of studies.
Sensitivity analyses
We undertook sensitivity analyses to investigate the impact of bias in the selection of participants, and bias in the conduct
and interpretation of the index test, on test performance.
Results 
Results of the search
Our search resulted in 37,555 citations, of which 527 full-text papers were assessed for eligibility. Of the 527, we
discarded 437 (82.9%). Of the remaining 90 papers, 17 were included, one paper was identified as an ongoing study,
33 were multiple publications of the included papers, and 39 papers were excluded for various reasons outlined in the
PRISMA flow diagram (Figure 1). No extra studies were found through reference checking though usable data for
four studies (Galluzzi 2010; Hertze 2010; Vos 2013; Zetterberg 2003) were identified through contacting authors of studies.
Included studies
The Characteristics of included studies table lists the characteristics of the 17 included studies involving a total of 2228
participants with cognitive decline but no dementia at baseline, of whom 2058 had analysable data. All but two of the
included studies used one version or another of the Petersen criteria for MCI; the other two used a CDR score of 0.5 to
define cognitive decline but no dementia. The Alzheimer's Disease Neuroimaging Initiative (ADNI) study (Shaw 2009
) referenced the full ADNI protocol where it was clear the Petersen criteria were used though this was not clear from
the actual manuscript. Of those 2057 participants, 703 developed Alzheimer’s dementia and 206 non-Alzheimer's
dementia. In addition, in one study (Herukka 2007) 33 participants were described as converting to dementia and though the
subtypes were described it was not possible (despite contact with author) to generate the required 2 x 2 table for Alzheimer's
disease dementia.
The median sample size of the included studies was 79 (range 37 to 588). All the studies were recent publications (2003
to 2013). Most of the studies (14/17) were conducted in Europe (six in Sweden, three in Italy, one in Finland, one in the
Netherlands, one in Spain, and one in Greece). There was one study conducted in both Sweden and the Netherlands,
two took place in the USA, and one in China. The participants were mainly recruited from secondary care (12 studies
from outpatient clinics and two studies from inpatient departments), two studies recruited the participants from the
community (Brys 2009; Fei 2011), and one from a mixed setting (Shaw 2009).
Excluded studies
Several hundred studies were discarded because they failed to satisfy two or more inclusion criteria. The proportion of
studies excluded because they failed to meet one of the four key inclusion criteria for the review was 39 out of 56
(69.6%) (Figure 1). The main reasons for exclusion were incorrect study design (cross-sectional rather than longitudinal) and
target population (not MCI participants at baseline) (see Figure 1). Two studies used a definition which was unclear for
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'cognitive decline no dementia' in their baseline population; two studies did not investigate conversion to Alzheimer’s
dementia or other dementias in the MCI sample included, rather they investigated different stages of cognitive decline. Ten
studies did not use thresholds for the Aß test instead reporting changes in plasma or CSF Aß42 levels over time. Two
studies used combined CSF Aß42 and tau index tests, and one study performed the index test at follow-up. Seventeen
papers were excluded as the data were not presented in a manner that allowed extraction to construct the necessary 2 x 2
table to generate sensitivities and specificities of the test, despite attempts made to contact authors.
Methodological quality of included studies
We assessed methodological quality using the QUADAS-2 tool (Whiting 2011).
Review authors’ judgments about each methodological quality item for each included study are presented in the
Characteristics of included studies table and Figure 2. The overall methodological quality of the included study cohorts is
summarised in Figure 3.
In the patient selection domain, we considered eight studies (47%) to be at low risk of bias because participants were
enrolled consecutively and inappropriate exclusions were avoided. In the review, we only included data on performance of
the index test to discriminate between patients with MCI who converted to dementia and those who remained stable;
therefore, we stated that a case-control design was avoided in all included studies. We considered four (24%) studies to be
at high risk of bias mainly because the participants were not consecutively or randomly enrolled. Five studies (29%) scored
unclear risk of bias due to poor reporting.
In the index test domain, we considered 10 studies (60%) to be at high risk of bias because the threshold used was not pre-
specified and the optimal cut-off level was determined from ROC analyses; therefore, the accuracy of the plasma and CSF
Aß biomarkers reported in these studies appeared to be overestimated. We considered seven remaining studies (40%) to be
at low risk of bias because the threshold used was pre-specified and the index test results were interpreted without
knowledge of the results of the reference standard.
In the reference standard domain, we judged six studies (35%) to be at low risk of bias because the reference standard used
was likely to correctly classify the target condition and clinicians conducting follow-up were not aware of the initial CSF
analysis results. We considered eleven remaining studies (65%) to be at unclear risk of bias due to poor reporting.
In the flow and timing domain, we considered nine studies (53%) to be of high concern for risk of bias because not all
patients were accounted for in the analysis or the time interval between the index test and reference standard was not
appropriate (duration of follow-up was shorter than one year). We considered eight remaining studies (47%) to be at low risk
of bias.
According to the QUADAS-2 assessment of applicability, we found few concerns that the included patients and setting, index
test, its conduct or interpretation, and the target condition (as defined by the reference standard) in each of the included
studies did not match the review question: could plasma and CSF Aß biomarkers identify those MCI participant with
Alzheimer’s disease pathology at baseline who would convert clinically to dementia at follow-up? However, due to the limited
number of included studies and levels of heterogeneity with respect to the three domains mentioned above, it was difficult to
determine to what extent the findings from a meta-analysis could be applied to clinical practice.
Findings
There were three target conditions for this review: [1] Alzheimer's disease dementia, [2] all forms of dementia, and [3] non-
Alzheimer's disease dementia, and our ability to present data for each was determined by what was undertaken within
each of the primary studies. There were also six possible index tests: [1] CSF Aß42, [2] CSF Aß40, [3] CSF Aβ42/Aβ40, [4]
plasma Aß42, [5] plasma Aß40, and [6] plasma Aβ42/Aβ40. However primary research for review was not available for most of
the possible combinations of target conditions and index tests.
All papers using NINCDS-ADRDA criteria presented data where probable Alzheimer's disease dementia (8) was the
outcome, or it was not stated (8).
The control group in each of the analyses below was formed by all participants who did not develop the outcome of interest,
therefore where Alzheimer's disease dementia was the outcome participants developing another form of dementia or MCI
non-converters were in the control group.
CSF Aß42 for detecting Alzheimer's disease dementia
The accuracy of Aß42 for Alzheimer's disease dementia was evaluated in 14 studies. The individual study estimates of
sensitivity and specificity from these 14 studies (1349 patients) are shown in Figure 4. The sensitivities were between 36%
and 100% while the specificities were between 29% and 91%. The summary ROC curve summarising the accuracy of Aß42
across all 14 studies, irrespective of the threshold used, is shown in Figure 5. Because of the variation in thresholds we did
not estimate a summary sensitivity and specificity. However, we derived estimates of sensitivity at fixed values of specificity
(see Table 1) from the model we fitted to produce the summary ROC curve. At the median specificity of 64%, the estimated
sensitivity was 81% (95% CI 72 to 87). This equated to a positive likelihood ratio (LR+) of 2.22 (95% CI 2.00 to 2.47) and a
negative likelihood ratio (LR–) of 0.31 (95% CI 0.21 to 0.48).
CSF Aß42 for detecting all forms of dementia
The accuracy of Aß42 for all forms of dementia was evaluated in four studies (464 patients) (Figure 6). The thresholds used
were between 209 mg/ml and 512 ng/ml. The sensitivities were between 56% and 75% while the specificities were
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between 47% and 76%. The summary ROC curve summarising the accuracy of Aß42 across all four studies, irrespective of
the threshold used, is shown in Figure 7. At the median specificity of 75%, the sensitivity was estimated to be 63% (22% to
91%) from the meta-analytic model. This equated to a LR+ of 2.51 (95% CI 1.30 to 4.86) and a LR– of 0.50 (95% CI 0.16 to
1.51).
CSF Aß42 for detecting non-Alzheimer's disease dementia
The accuracy of Aß42 for non-Alzheimer's disease dementia was evaluated in three studies (385 patients). Since there were
very few studies and considerable variation in test performance, the results were not meta-analysed. Study specific
estimates of sensitivity and specificity are summarised in Figure 8 and Figure 9. The sensitivities were between 8% and 63%
while the specificities were between 35% and 67%. The study that did report the lowest threshold had a low sensitivity and
the lowest specificity.
CSF ratio Aβ42/Aβ40 for detecting Alzheimer's disease dementia
The accuracy of the CSF Aβ42/Aβ40 for Alzheimer's disease dementia was evaluated in two studies (199 patients). The
sensitivities were between 64% and 88% while the specificities were between 70% and 78%.
Plasma Aß42 and plasma Aβ42/Aβ40 ratio for detecting Alzheimer’s disease dementia
The accuracy of these plasma Aβ biomarkers for Alzheimer's disease dementia was evaluated only in one study (565 and
562 patients respectively). The sensitivity was 86% while the specificities were 50% and 70% respectively.
Investigations of heterogeneity
Investigations of heterogeneity were performed to assess the effect of pre-specifying the threshold on the accuracy of Aß42
for Alzheimer's disease dementia. Test performance did not differ significantly (P = 0.8) between studies that pre-specified
the threshold (n = 6) and those that only determined the threshold at follow-up (n = 8). The summary ROC curves for the two
groups of studies are shown on the summary ROC plot in Figure 10. There is a paucity of knowledge around thresholds for
Aß42 for Alzheimer's disease dementia. Despite best efforts a reliable and valid threshold remains elusive for clinical practice
and research. Our findings also raise issues around risk of bias and the appropriateness of artificially determining cut-offs.
We were unable to investigate the effect of duration of follow-up due to substantial variation in study length and reporting. For
instance, some studies measured mean and standard deviation, or the range of duration of follow-up, while others measured
only the median or mean and standard deviation for conversion period. Poor reporting of patient demographic information
also contributed to unknown sources of heterogeneity. Due to variation and missing variables, and insufficient number of
studies we could not adequately compare patient characteristics between studies. Finally, as the Peterson criteria were used
in the majority of studies to diagnose MCI there were not enough studies to investigate different MCI criteria for sources of
heterogeneity.
Sensitivity analyses
We undertook sensitivity analysis by excluding one study (Kester 2011) from the analysis of CSF Aß42 for predicting
conversion to Alzheimer's disease dementia, because the authors excluded a sample of MCI non-Alzheimer's disease
converters from their analysis. Exclusion of this study made no difference to our results (Table 1). A second sensitivity
analysis was undertaken to assess the effect of risk of bias in the patient selection domain on our findings. Eight studies (n =
950 patients) were considered at high (n = 3) or unclear (n = 5) risk of bias. The exclusion of these studies made no
difference to our findings. A third sensitivity analysis involved the index test domain; 8 studies (n = 560 patients) were
considered to have a high risk of bias. Exclusion of these studies had no impact on our findings.
Discussion 
Summary of main results
We included 17 studies in the review. Although we did not specify inclusion based on the use of the term 'mild cognitive
impairment (MCI)' to describe 'cognitive impairment but no dementia', all of the included studies defined their baseline
population using the MCI criteria. We will therefore use the term MCI in the remainder of this discussion.
The meta-analysis of the accuracy of CSF Aβ42 for conversion from MCI to Alzheimer's dementia is based on the results
from 14 studies. Three studies were included in the meta-analysis of the accuracy of CSF Aβ42 for conversion from MCI to
non-Alzheimer's disease dementias and four studies for conversion from MCI to all forms of dementia. Only one study
reported the use of plasma Aβ42 levels or the plasma ratio Aβ42/Aβ40 for the delayed verification of Alzheimer's disease
dementia, which yielded the same sensitivity of 86% (95% CI 81 to 90) and specificities of 50% (95% CI 44 to 55) and 70%
(95% CI 64 to 75) for plasma Aβ42 and plasma Aβ42/Aβ40 ratio respectively.
The total number of MCI participants at baseline was 2228. The accuracy of plasma and CSF Aβ biomarkers was
evaluated in 2058 participants, of whom 703 developed Alzheimer's disease dementia and 186 non-Alzheimer's
disease dementia. Fourteen studies used one of the Petersen diagnostic criteria of MCI (Petersen 1999; Petersen 2004; 
Petersen 2006), highlighting the dominance of this description of the individual with objective cognitive impairment
but no dementia. Two papers used the CDR value of 0.5 as their definition of cognitive impairment but no dementia.
Studies were variable in duration of follow-up, with a range from six months to eight years (Appendix 4). In general, studies
with a longer length of follow-up tended to show higher sensitivities as a consequence of the greater number converting to
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dementia in their cohorts as a function of time. The accuracy of low levels of CSF Aß42 in the 17 included studies
ranged from specificities of 29% (Shaw 2009) to 91% (Parnetti 2006) and sensitivities from 8% (Galluzzi 2010) to
100% (Papaliagkas 2009). The main utility of CSF Aß42 in the proposed new criteria is the specificity of lowered CSF Aβ42 to
identify Alzheimer's disease in people with cognitive impairment but no dementia. We evaluated 14 studies and obtained a
summary sensitivity of 81% (95% CI 72 to 87) from the summary ROC curve at the median specificity of 64% (the range of
specificity from the included studies was 29% to 91%). This test appears to have low specificity and only modest sensitivity
rather than having the desired specificity for Alzheimer's disease proposed in the new criteria.
Strengths and weaknesses of the review
This review took place after extensive discussion within The Cochrane Collaboration regarding the optimal methodology to
determine the test accuracy of wet lab biomarkers, imaging modalities and neuropsychological tests for neurodegenerative
disease present before the development of dementia. There is a major impetus in this area, driven by both clinical need and
the limitations of existing diagnostic criteria, to support discovery of more effective treatments for dementia. Newly proposed
criteria have emphasised the integration of biomarker criteria with cognitive criteria with the aim of improving the specificity of
diagnosis prior to dementia onset. This review used specific criteria to answer the question, which yielded a reasonably large
dataset given the challenges of conducting the primary research in what remains a relatively undeveloped research area.
The oldest publication in our data set was from 2003 and 13 of the included studies were published within the last five years.
In its own right this would raise concerns about the validity of the proposed criteria, which were published in 2010 and 2011
and therefore relied on a small dataset to form conclusions with no published meta-analysis of those studies available at the
time. This review is the first such systematic review of this emerging literature base. Although there were 17 studies in the
review that contributed to the conclusions, the review is limited by the large number of studies that have taken place and
which probably had data that could have been used in the review but, despite contact with authors, did not present the
results in a manner that could be extracted and used. It is hoped that future revisions of this review will have access to these
datasets or data yet to be published from ongoing studies that will be presented in the appropriate format. In these papers,
data were presented as mean difference between groups of patients with stable MCI and those who converted to Alzheimer’s
dementia, in effect exploratory studies determining statistical associations between disease progression and the biomarker
rather than the clinical utility of these markers in diagnostic terms. This observation reflects the predominantly exploratory
nature of the use of these biomarkers for identifying disease process rather than as diagnostic tests with clinical utility, in
effect representing phase 2 proof of concept studies as opposed to later stage phase 3 clinically useful studies.
Despite this, the findings from our review are entirely consistent with the JAMA paper (Mattsson 2009) that had access
to full data sets from seven studies (Bjerke 2009; Brys 2009; Chiasserini 2010; Hansson 2007; Herukka 2007; Kester 2011; 
Parnetti 2006) of the 17 studies included in our review. Their optimal sensitivity and specificity were virtually identical to
the ones we generate from our summary ROC curve, giving our findings external validity (Table 1). It is considered
unlikely, therefore, that the inclusion of other studies in our review would have had much impact on our summary of the
accuracy of lowered CSF Aβ42 for diagnosing Alzheimer’s disease in a population with cognitive decline but no dementia.
Although the quality of the papers reported in our analysis was generally good, overall the methodological and reporting
quality of all considered papers was poor. An international consensus initiative (the STARDdem Initiative) was
conducted recently, co-ordinated by the Cochrane Dementia and Cognitive Improvement Group. This initiative aimed to
review the current standard of reporting in diagnostic test accuracy studies and cognitive impairment and to generate
enhanced guidance to the existing reporting guideline for diagnostic test accuracy studies (Noel-Storr 2013; the
STARDdem Initiative website). This developing research field would be supported by acceptance of consistent
methodologies and reporting which would assist future reviews of the diagnostic accuracy of tests and their synthesis in
meta-analysis.
The small number of studies included in our review precluded formal statistical analysis of the effect of potential sources of
heterogeneity. We observed that longer duration studies tended to yield greater sensitivity. As age is the key risk factor for
Alzheimer’s disease dementia, it stands to reason that as the cohort ages the incidence of dementia will increase, improving
the sensitivity of the test in question. In effect the number of false positives diminishes as a function of time. However, formal
analysis of the influence of these factors on the accuracy of CSF Aβ was not possible as age, ApoE status, duration of MCI
prior to cohort entry, gender and cognitive function at baseline were not consistently reported.
Most of the studies (14) were conducted in western Europe, two in the USA and one in China. Overall, the ethnic distribution
of the population being studied was unclear from the reports. It is also noteworthy that individual studies in the most part
generated their own optimal cut points for what constituted a positive or negative test. Such inconsistency is being addressed
currently, though the genesis of uniform analysis techniques and thresholds will not alter the diagnostic accuracy of the test
but will allow for easier integration of results across studies.
Applicability of findings to the review question
Although there were differences between studies, including test threshold, we suggest that low CSF Aβ42 should not be used
as a diagnostic test for Alzheimer’s disease in patients with cognitive decline but no dementia. The test is invasive, costly,
suffers from a lack of consensus on sampling and analysis, and is non-specific. It does not have the necessary accuracy to
aid the clinician in making decisions as to which of their patients with cognitive decline but no dementia are likely to develop
Alzheimer's dementia.
Recently proposed diagnostic criteria for prodromal AD emphasise low CSF Aβ42 in isolation from any other biomarker test
as indicating ‘likely’ Alzheimer’s disease in a patient population with objective cognitive impairment. This proposal is not
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supported by our findings and the evidence points in the opposite direction where a normal test may have some modest
utility in suggesting that normal CSF Aβ42 may rule out Alzheimer’s disease; even in this regard the risks and cost of testing
may outweigh the potential benefit.
Authors' conclusions 
Implications for practice 
In 2009, Petersen wrote that the use of CSF biomarkers was of value in clinical research, specifically stratification for
clinical trials, but lacked the necessary accuracy for clinical practice. This meta-analysis endorses that view. The
proposed criteria for prodromal dementia would allow a diagnosis of prodromal Alzheimer's dementia to be made in
the presence of low CSF Aβ in a person with significant amnestic symptoms. This review does not support this. It is
possibly the case that in concert with other biomarker tests, be they imaging or other CSF markers, a reasonable
accuracy can be obtained. The proposed criteria should be adapted at this stage in light of our findings that as a
single test CSF Aß lacks the accuracy to diagnose Alzheimer's disease in patients with cognitive impairment but no
dementia. That said, sequential testing with different tests is limited by the important assumption that each of the
tests is conditionally independent of each other; this would not be the case for example with PET-PiB and CSF Aβ,
which are highly correlated measures of the same pathological process. To illustrate the lack of value of this test, if
over a three-year period 20% of people with MCI will go on to develop Alzheimer’s dementia, the pre-test probability
is 20% on the basis of the clinical diagnosis alone (Mitchell 2009). In these patients, a low level of CSF Aβ42 and a
LR of 2.22 would yield a post-test probability of 36% or an increment in risk of developing Alzheimer's dementia of
16%. Conversely, given a negative test result and a negative LR of 0.31, the post-test probability of that person
developing Alzheimer’s dementia is 7.2%; a decrement in risk of developing Alzheimer's dementia of 12.8%. There
have been recent initiatives to screen primary care populations for cognitive impairment and refer those who screen
positive to specialist care for further evaluation. In effect this may identify large populations with cognitive impairment
but no dementia who are not seeking health care themselves. It is known that when applying the Petersen criteria in
population and primary care settings the conversion rate to Alzheimer's dementia is lower than in secondary care
services (Mitchell 2009). The effect therefore of identification of an at risk population in primary care would be to in effect
reduce the pre-test probability. As likelihood ratios are a function of the test, the effect of reducing the pre-test probability
on the incremental benefit of abnormal CSF Aβ42 is shown in Figure 11. This shows that the incremental benefit of an
abnormal CSF Aß level in a patient identified through screening of primary care populations is substantially less than the
already low figures achieved in a secondary care population. This is a theoretical conclusion as no studies in our sample
were conducted in an explicitly defined primary care population, however in primary care it is likely that the pre-test
probability for Alzheimer's dementia is lower than it would be in a secondary care 'memory clinic' population. The optimal pre-
test probability for incremental benefit of a positive test is 40%, and 64% for a negative test, but even at this optimum level
the benefits are modest. The results of this review are that abnormal CSF Aß levels are of little value in patients referred to
specialists services and of even less value in those in whom cognitive impairment but no dementia is identified through
primary care screening.
Implications for research 
The observations we have made regarding the utility of CSF Aß in identifying Alzheimer's disease prior to the onset of
dementia suggest that at least at the MCI phase of illness there is little utility in its use. However, future research may identify
that at even earlier stages (younger individuals) an accumulation of Aß in the brain as manifested through low CSF Aß will
have greater specificity for indicating pathology rather than being a consequence of normal ageing in the elderly. Moreover,
more uniform approaches to thresholds, analysis and study conduct, in particular uniformity of length of follow-up, may
provide a more homogenous estimate than was available here. The exploration for better, more accessible and more
accurate biomarkers with, in particular, better specificity are urgently required. This research effort should be stimulated by
the observation that CSF Aß does not appear to have the accuracy to draw to a conclusion the search for more accurate
biomarkers for Alzheimer's disease. However, where clinical trials using specific anti-amyloid therapies would benefit from
small incremental changes towards improved post-test probabilities, then CSF Aß may be useful in enriching the population.
Our work, summarised in Figure 11, perhaps illustrates best the additional accuracy that can be achieved by using this test
and the trial sponsors can apply this empirical evidence in their selection criteria for studies.
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Differences between protocol and review 
In the protocol we stated that we will consider MCI participants who have been diagnosed using any of the 16
definitions of MCI (Matthews 2008). In our review we also included participants whose clinical diagnosis of MCI was based
on the CDR = 0.5 criteria.
Published notes 
Characteristics of studies
Characteristics of included studies 
Bjerke 2009
Patient Selection
A. Risk of Bias
Patient Sampling
174 consecutive participants with mild cognitive
impairment and 52 healthy elderly controls. We
only included data on performance of the index
test to discriminate between patients with MCI who
convert to dementia and those who remained
stable.
Exclusion criteria: acute/unstable somatic disease;
severe psychiatric disorder (e.g. major depression,
psychotic disorder, bipolar disorder); substance
abuse; confusion caused by medication
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
174 MCI participants from the Goteborg study
diagnosed by the Petersen 1999 and Winbald
2004 criteria at baseline. Baseline
demographic data reported for 162 participants
Gender: 68 men; 94 women. MCI-MCI: 53 M;
65 F; MCI-SVD: 5 M; 4F; MCI-MD: 2 M; 13 F;
MCI-AD: 8 M; 12 F
Age: mean 66.75 years; MCI-MCI 62 (57-68)
years; MCI-SVD 68 (66-74) years; MCI-MD 69
(65-74) years; MCI-AD 68 (58-72) years
APOE ε4 carrier: 86; MCI-MCI 54/118 (46%);
MCI-SVD 6/9 (67%); MCI-MD 12/15 (80%);
MCI-AD 14/20 (70%)
MMSE: MCI-MCI: 29 (28, 30); MCI-SVD: 28
(26, 28); MCI-MD: 28 (26, 29); MCI-AD 28 (27.
29)
Setting: secondary care, outpatients - memory
clinic, Goteborg, Sweden
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
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Index tests
CSF: Abeta42
LP through L3/L4 or L4/L5 interspace; CSF, collected in polypropylene tubes, was submitted to
centrifugation at 2,000 g at +4°C for 10min. The CSF analysis on A 42 levels were performed on a
single occasion by the standardised Luminex xMAP technology. Raw data from the Luminex assay
were normalized to ELISA concentrations of abeta42 by running the same samples with both methods.
A stable batch of ELISA reagents was used for all comparisons.The limit of detection for Abeta 42 was
61 ng/L
Threshold: 512 ng/l determined at follow-up (the case-control derived threshold was applied) (Fig.1c,
p351)
At baseline 162 MCI:101 with 'normal CSF abeta42 level'; 61 with 'abnormal CSF abeta42 level'
Index test was conducted before follow-up
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease
dementia or other forms of dementia
Reference standards: NINCDS-ADRDA
and ICD-10 criteria for Alzheimer's disease
dementia; DSM-III-R and ICD-10 criteria for
other dementia
Unclear whether clinicians conducting
follow-up were aware of initial CSF analysis
results
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Duration of follow-up: 4 years
At baseline=174 MCI: 44 MCI-converters (20
MCI-AD; 15 MCI-MD; 9 MCI-SVD); 8 with normal
cognition; 3 converted to dementia with unknown
cause; 1 converted to primary progressive
aphasia
36 patients converted to dementia within 2 years
and 8 patients within 4 years
Number included in analyses=162
TP=18; FP=43; FN=2; TN=99 for conversion to
Alzheimer's disease dementia (Fig 1, p351)
TP=33; FP=28; FN=11; TN=90 for conversion to
all dementias (Fig 1, p351)
TP=15; FP=46; FN=9; TN=92 for conversion to
non-AD dementia (Fig 1, p351)
Loss to follow-up: 12 patients were excluded
from further analysis (8 patients had improved
their condition at follow-up; 3 patients converted
to a dementia disorder where no etiology could
be clinically established; 1 patient converted to
primary progressive aphasia) (p350)
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Blom 2009
Patient Selection
A. Risk of Bias
Patient Sampling
58 patients with MCI, 47 with AD and 35 healthy
elderly controls. Patients with AD and MCI were
recruited consecutively from patients at a
university hospital who underwent lumbar
puncture as part of their dementia investigation
between 1993 and 2001; control subjects were
mainly spouses of participants. We only
included data on performance of the index test
to discriminate between patients with MCI who
convert to dementia and those who remained
stable.
No exclusion criteria were reported
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
58 participants diagnosed by the Petersen
1999 criteria at baseline; 28 MCI patients
revisited the clinic.
Gender: 28 men; 30 women
Age: mean 62.9 years; MCI-MCI 61.3 years;
MCI-AD 71.7 years; MCI-Progressors 66.0
years
APOE ε4 carrier: 20
MMSE: not reported
Setting: Secondary care, outpatients -
Department of Geriatrics, Huddinge, Sweden
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
CSF: Abeta42
Following standard lumbar puncture, the CSF sample was aliquoted and stored at –80°C until
quantification. Levels of A 42 and A 40 were analysed using a well-characterized ELISA with BNT77
(mouse IgA anti-A 11–28; Takeda, Osaka, Japan) and horseradish peroxidase-conjugated detector
antibodies (BA27 IgG2 mouse anti-A 40 and BC05 IgG1 mouse anti-A 42).
Threshold: 82 pM for Abeta 42 determined at follow-up (the case-control derived threshold was
applied) (p 460 and Fig.2c, p 462)
At baseline 28 MCI who had a follow-up assessment: 10 with 'normal CSF abeta42 level'; 18 with
'abnormal CSF abeta42 level'
Index test was conducted before follow-up
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease
dementia
Reference standard: NINCDS-ADRDA
criteria
Unclear whether clinicians conducting
follow-up were aware of CSF biomarker
results
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Duration of follow-up: Range: 3-12 years (mean
± SD 5.6 ± 2.7 years) for MCI-MCI (stable); 1-8
years (mean ± SD 3.4 ± 2.1 years) for MCI-AD
(converters)
28 MCI: 14 MCI-MCI; 14 MCI-AD
Number included in analyses=28: 10 with
'normal CSF abeta amyloid level': 5 MCI-MCI; 5
MCI-AD; 18 with 'abnormal CSF abeta amyloid
level': 9 MCI-MCI; 9 MCI-AD (Fig 2, p462)
TP=9; FP=9; FN=5; TN=5 (Fig 2, p462)
Loss to follow-up: 30 MCI participants; no
reasons were reported
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? High risk
Notes
Notes There is no overlap between Bloom 2009 and Zetterberg 2003 studies regarding the
participants (Dr Zetterberg's email on 04/10/13)
 
Brys 2009
Patient Selection
A. Risk of Bias
Patient Sampling
65 consecutive participants with MCI and 21
healthy elderly controls. Healthy controls were
not included in the analysis of CSF markers for
the prediction of conversion of MCI to AD.
Exclusion criteria: medical conditions or a
history of significant conditions that may affect
brain structure or function (e.g. stroke, fronto-
temporal and Lewy body dementia,
depression, uncontrolled hypertension or type
II diabetes); MRI-based evidence of lacunar or
cortical infarctions
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
DTA1 Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other demen...
17 / 79
B. Concerns regarding applicability
Patient characteristics and setting
65 community-dwelling participants with MCI at
baseline; the diagnosis of MCI was based on:
progressive memory complaints corroborated by
an informant, a CDR=0.5, GDS score = 3 and
clinically recognisable memory impairment
without fulfilling either the DSM-IV or NINCDS-
ADRDA criteria for Alzheimer's disease dementia.
Gender: 34 men; 31 women
Age: 72.1 years MCI-MCI; 71.3 years MCI-AD
APOE ε4 carrier: 33
MMSE: MCI-MCI: 28.1±1.7; MCI-AD: 27.3±2.1
Setting: community care, New York, USA
There were no significant differences in baseline
demographic characteristics between healthy
controls and MCI participants who did or did not
progress to AD
Are there concerns that the included patients and setting do not match
the review question? Low concern
Index Test
Index tests
CSF: Abeta42/Abeta40 ratio
All subjects underwent lumbar puncture within 3 months of their longitudinal clinical assessment
periods. CSF was stored at -80°C. The CSF amyloid β levels (Aβ40, Aβ42) were measured using a
monoclonal antibody 6E10 (specific to an epitope present on Aβ-16) and to rabbit antisera to Aβ40 and
Aβ42 respectively, in a double antibody sandwich ELISA
Threshold(s): the detection limit for both Aβ40 and Aβ42 was 10 pg/ ml (p 3)
Optimal cut-off level was determined from ROC analysis, with consideration to the recommendation
(AD diagnostic tests Consensus Working Group) that sensitivity should be >80%; the value of the
threshold was not reported
At baseline 65 MCI: 29 with 'normal CSF abeta42/abeta40 ratio level'; 36 with 'abnormal CSF
abeta42/abeta40 ratio level'
Index tests were conducted before clinical follow-up
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease
dementia
References standard: NINCDS-ADRDA
criteria; DSM-IV criteria
"The creation of study groups was solely
based on the clinical diagnosis and was
blinded to all CSF results" (p2)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: 2±0.7 years for MCI-
MCI and 2.1±0.5 years for MCI-AD
At follow-up: 65 MCI: 43MCI-MCI; 22 MCI-AD
(Abstract)
Sensitivity 63%; Specificity: 69% for
conversion to AD (p5)
Number included in analyses=65 MCI: 29 with
'normal CSF abeta42/40 amyloid level': 26
MCI-MCI; 3 MCI-converters; 36 with
'abnormal CSF abeta amyloid level': 17 MCI-
MCI; 19 MCI-converters
TP=14; FP=13; FN=8; TN=30
Loss to follow up: data were reported for all 65
MCI participants
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Chiasserini 2010
Patient Selection
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A. Risk of Bias
Patient Sampling
98 participants attending a centre for memory
disturbances in the period 2003-2008. No
further details of recruitment procedure
reported. 32 participants had probable AD, 41
participants had MCI; 25 age-matched
participants, without signs of cognitive
impairment, who underwent CSF analysis for
other reasons (headache, suspected
myopathy, etc) were also included. We only
included data on performance of the index test
to discriminate between patients with MCI who
convert to dementia and those who remained
stable.
No exclusion criteria were reported
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
41 participants diagnosed by the Petersen
1999 criteria at baseline
Gender: 20 men; 21 women; MCI-MCI: 8 M;
10 F; MCI-AD: 12 M; 11 F
Age: 65.39 years; MCI-MCI: 64.61±8.10; MCI-
AD: 67.17±7.71
APOE ε4 carrier: not reported
MMSE: MCI-MCI: 27.61±1.46; MCI-AD:
26.91±1.57
Setting: secondary care, outpatients - Center
for Memory Disturbance, Perugia, Italy
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
CSF: Abeta42
LP was performed in the morning, after overnight fasting, following a standardised procedure. CSF
was collected in polypropylene tubes, gently mixed to avoid possible gradient effects, centrifugated at
1200 x g for 10 min, aliquoted and stored at -80ºC. Abeta1-41 was measured using commercially
available ELISA (no details reported).
Threshold(s): 741pg/ml; determined at follow-up from ROC analysis (Fig.1, B, p1284)
At baseline 41 MCI: 22 with 'normal CSF abeta1-42 level'; 19 with 'abnormal CSF abeta1-42 level'
Index test was conducted before clinical follow-up
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease
dementia
Reference standard: NINCDS-ADRDA
criteria
Unclear whether clinicians conducting
follow-up were aware of CSF biomarker
results
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: 4 years (annual follow-up;
mean follow-up not reported)
At follow-up: 41 MCI: 23 MCI-AD; 18 MCI-MCI
(p1282)
Number included in analyses=41: 22 with
'normal CSF abeta amyloid level': 16 MCI-MCI;
6 MCI-AD; 19 with 'abnormal CSF abeta
amyloid level': 2 MCI-MCI; 17 MCI-AD (Fig 1B)
TP=17; FP=2; FN=6; TN=16 (Fig 1B)
Loss to follow-up: follow-up data appear to have
been available for all MCI participants
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Fei 2011
Patient Selection
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A. Risk of Bias
Patient Sampling
Participants were selected by random sampling of
community-dwelling elders (>65 years) from eight
communities. Participants had to be native Chinese
speakers, physically able to participate in study home
visits, have no clinical diagnosis of dementia, consent to
annual assessment, and have sufficient vision and hearing
to complete neuropsychological tests. Participants meeting
these criteria were assessed for eligibility based on
presence of MCI (588 participants).
Exclusion criteria: major depressive disorder;
schizophrenia; substance abuse; mental retardation
according to DSM-IIIR; cerebrovascular disorders,
hydrocephalus, intra-cranial mass; abnormalities in serum
folate and vitamin B12; syphilis serology; abnormalities in
thyroid hormones; history of traumatic brain injury or other
neurological disease; significant medical problems (e.g.
poorly controlled diabetes or hypertension, cancer within
the last 5 years, clinically significant hepatic, renal, cardiac
or pulmonary disorders); use of psychotropic agents,
nontropic drugs, cholinergic or anticholinergic agents ,
antiplatelet agents, anticoagulants, steroids, or
serotoninergic drugs, unless a 14 day wash-out had been
observed
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
588 participants diagnosed with MCI by the
Petersen 2001 criteria at baseline
Demographic characteristics reported on 572
participants
Gender: 209 men; 363 women. MCI-MCI: 113 M;
127 F; MCI-AD: 67 M; 178F; MCI-other
dementias: 29 M; 58 F
Age: MCI-MCI: 66±4.3 years; MCI-AD:74±3.6;
MCI-other dementias: 75±3.9
APOE ε4 carrier: 290; MCI-MCI: 74/240 (31%);
MCI-AD: 171/245 (66%); MCI-other dementias:
45/87 (52%)
MMSE: MCI-MCI: 27.4±1.7; MCI-AD:26.3±1.5;
MCI-other dementias: 26.9±1.4
Setting: community setting; index test assessed in
the tertiary care - research centre, Taiyuan city,
China
Are there concerns that the included patients and setting do not match
the review question? Low concern
Index Test
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Index tests
Plasma: Abeta42; Plasma Abeta42/Abeta 40 ratio
Fasting morning plasma, drawn into ethylendiaminetetraacetic acid tubes. Samples spun immediately
(10 min, 3000 rpm, 4ºC) and separated samples stored in polypropylene tubes at -80ºC. The plasma
Abeta40 and Abeta42 peptide assay was performed using a sandwich enzyme-linked immunosorbent
assay constructed to specifically measure abeta amyloid. Plasma samples were assayed in triplicate
on two 96-well microtiter EUSA plates coated with R162 or R165. This method allowed the
quantification of both lengths of Abeta and the ratio of the more aggregable form of the protein.
Abeta40 and Abeta42 were simultaneously analysed. All peptide level measurements were performed
in duplicate.
Threshold(s): the optimal cut-off values: 0.64 ng/ml for Abeta42; 0.95 ng/ml for Abeta42/40 ratio;
determined at follow-up from ROC analysis (p 94)
Index test was conducted before clinical follow-up
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease
dementia or other forms of dementia
Reference standard: DSM-III-R criteria;
NINCDS-ADRDA criteria; NINDS-AIREN
Internatinal criteria; McKeith et al criteria
Clinicians conducting follow-up were
blinded to the initial CSF analysis results
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Duration of follow-up: mean 5.2 years (range 4-6.8
years)
At follow-up: 565: 332 MCI-converters (245 MCI-AD; 87
MCI-other dementias); 233 MCI-MCI for plasma
Abeta42; 562: 332 MCI-converters (245 MCI-AD; 87
MCI-other dementias); 230 MCI-MCI (p94)
For plasma Abeta42 a number included in analyses
=565; sensitivity=85.7% and specificity=49.6% for
conversion to AD dementia (p 94); TP=210; FP=161;
FN=35; TN=159
For plasma Abeta42/Abeta 40 a number included in
analyses=562; sensitivity=85.7% and specificity=69.7%
for conversion to AD dementia (p94);TP=210; FP=96;
FN=35; TN=221
Loss to follow-up: 23 for plasma Abeta 42 (13 died
before the last follow-up ended; 7 dropped out because
of adverse effects; 3 uninterpretable data); 26 for
plasma Abeta42/Abeta 40 ratio (13 died before the last
follow-up ended; 7 dropped out because of adverse
effects; 6 uninterpretable data)
Withdrawals explained? Yes N=588; 13 participants
died before the last follow-up; 7 participants dropped
out because of adverse effects
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Galluzzi 2010
Patient Selection
A. Risk of Bias
Patient Sampling
108 consecutive participants with MCI,
referred to an outpatient memory clinic over
24 months
Participants were excluded if they had a
history or presence of neurological signs of
major stroke
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
90 participants, who had diagnosed by the
Petersen 1999 criteria at baseline and had
follow-up assessment, were included in the
study; CSF was obtained from 64 participants.
Demographic data are reported on 90
participants.
Gender: 37 men; 53 women
Age: mean 72.05 years; MCI-MCI: 70.09±7.1;
MCI-AD: 72.2±7.1; MCI-nAD: 25.5±1.9
APOE ε4 carrier: 35; MCI-MCI: 19; MCI-AD: 14;
MCI-nAD: 2
MMSE: MCI-MCI: 26.3±1.9; MCI-AD: 26.4±1.6;
MCI-other dementia: 73.0±7.1
Setting: secondary care, outpatients -
Translational Outpatient Memory Clinic
(TOMC), Brescia, Italy
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
CSF: Abeta42
CSF was obtained by lumbar tap between L4 and L5 or L3 and L4 and processed as detailed
elsewhere (Frisoni 2009). Levels of Abeta42 protein was determined by commercially available
enzyme linked immunosorbent assay (Innogenetics, Belgium).
Threshold(s): <500 pg/ml; determined at baseline and based on published criteria (p 2006)
At baseline 64 MCI: 29 with 'normal CSF Abeta42 level'; 35 with 'abnormal CSF Abeta42 level'
Index test was conducted before clinical follow-up
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease
dementia or other forms of dementia
Reference standard: NINCDS-ADRDA
criteria
Unclear whether clinicians conducting
follow-up a were aware of initial CSF
analysis results
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Duration of follow-up: 24.0 ± 9.7 months
At follow-up: 39/90 participants converted to
dementia (Abstract)
Number included in analyses=64: 29 with 'normal
CSF Abeta42 amyloid level':15 MCI-converters (4
MCI-AD probable; 11 MCI-non-AD); 14 MCI-MCI;
35 with 'abnormal CSF Abeta42 amyloid level': 19
MCI-converters (16 MCI-AD probable; 2 MCI-AD
possible; 1 MCI-non-AD); 16 MCI-MCI (from Dr
Galluzzi's emails)
TP=18; FP=17; FN=4; TN=25 (conversion to AD
dementia)
TP=19; FP=16; FN=15; TN=14 (conversion to all
dementia)
TP=1; FP=34; FN=11; TN=18 (conversion to non-
AD dementia)
Loss to follow-up: 44 (16 refused follow-up
assessment; 2 did not follow-up due to logistic
problems; 24 refused LP; 2 failure to reach the
arachnoid space due to osteoarthrosis)
Withdrawals explained? No 18 participants from
the consecutive sample (N=108) were excluded
from the study because they did not have a follow-
up assessment. CSF was not available from 26/90
participants: 24 participants refuse the LP
procedure; 2 LPs were not performed due to
osteoarthrosis
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? High risk
Notes
Notes The trial investigators contacted; they provided data tor the 2x2 table to be completed;
emails from Dr Galluzi on 30/3/12 and 5/1/13
 
Hampel 2004
Patient Selection
A. Risk of Bias
Patient Sampling
93 participants with probable AD, 52 with MCI,
and 10 healthy, age-matched controls were
recruited from a hospital rehabilitation
department. We only included data on
performance of the index test to discriminate
between patients with MCI who convert to
dementia and those who remained stable.The
MCI group was not a consecutive sample and
was selected at follow-up.
No exclusion criteria were specified
Was a consecutive or random sample of patients enrolled? No
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
52 MCI participants diagnosed by the Petersen
1999 criteria at baseline
Gender: 24 men; 28 women
Age: mean age 72.6 years (range 54–87)
APOE ε4 carrier: not reported
MMSE (all MCI): 28.9±1 (range 26-30)
Setting: secondary care, inpatients - Department
of Rehabilitation, Pitea, Sweden
Are there concerns that the included patients and setting do not match
the review question? Low concern
Index Test
Index tests
CSF: Abeta42
CSF Abeta 1-42 to predict conversion from MCI to AD
CSF samples were taken by lumbar puncture, collected in polypropylene tubes, and stored at -80ºC.
Abeta1–42 was measured in duplicate using a commercial ELISA (Innotest beta-amyloid 1-42,
Innogenetics, Belgium)
Threshold(s): <679 ng/l, established in the MCI-MCI versus MCI-AD at follow-up (p707)
At follow-up: 18 with 'normal CSF Abeta42 amyloid level': 13 MCI-MCI; 5 MCI-AD; 34 with 'abnormal
CSF Abeta42 amyloid level': 10 MCI-MCI; 24 MCI-AD
Index test was conducted before clinical follow-up
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease
dementia
Reference standard: NINCDS-ADRDA
criteria; DSM-IV criteria
Unclear whether clinicians conducting
follow-up a were aware of initial CSF
analysis results
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Duration of follow-up: mean 8.4±5.1 months
(range 2-24 months); follow-up interval for
converters was 9.6±5.4, and for non-
converters 7.0±4.3 months
At follow-up: 52 MCI: 29 MCI-AD; 23 MCI-
MCI (p94)
Number included in analysis=52; Sensitivity
83%; Specificity 57% (p707); D+ 29: D- 23
TP=24; FP=10; FN=5; TN=13
Loss to follow-up: data for all 52 MCI
participants were reported
Was there an appropriate interval between index test and reference
standard? No
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? High risk
Notes
Notes  
Hansson 2007
Patient Selection
A. Risk of Bias
Patient Sampling
137 patients with MCI, who had sought
medical advice for subjective memory
difficulties and from whom CSF was
obtained at baseline, recruited at a
University hospital. 36 healthy controls were
also included, but appear to have been
used for comparison purposes only and not
included in the ROC analysis.
No exclusion criteria were specified
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
137 participants diagnosed by the Petersen 1999
criteria. Baseline demographic data reported for 131
participants
GENDER: 58 men; 73 women             
AGE (median): MCI-MCI (stable) 65 years; MCI-AD
75 years; MCI-other dementia 76 years; range
50-85 years
APOE ε4 carrier: not reported
MMSE: MCI-MCI 27.3±1.8; MCI-AD 26.9±1.4; MCI-
other dementia 27.0±1.5
Setting: secondary care, outpatients - memory
disorder clinic, University hospital, Malmo, Sweden
Are there concerns that the included patients and setting do not match
the review question? Low concern
Index Test
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Index tests
CSF: Abeta42; Abeta42/Abeta40 ratio
Abeta42 and Abeta40 concentrations were determined by commercially available ELISA kits (The
Genetics Company) using the capture antibody W02 (epitope Abeta5–8) and the detection antibodies
G2–10 for A 40 and G2–13 for A 42
Threshold (s) : determined at follow-up (p 318); ROC analyses were used to identify optimal cut-offs:
0.64 ng/ml for Abeta42 and 0.95 ng/l for Abeta42/Abeta40 ratio
Index test was conducted before clinical follow-up
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease dementia or
other forms of dementia
Reference standards: NINCDS-ADRDA and DSM-
III-R for Alzheimer's disease dementia; DSM-III-R
for vascular dementia; McKeith for Lewy bodies
dementia and Brun for frontotemporal dementia
Unclear whether clinicians conducting follow-up
were aware of CSF biomarker results
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Duration of follow-up: range: mean: 5.2 years (4-6.8
years)
At follow-up:134 MCI: 57 MCI-AD; 21 MCI-other
dementias (15 SVD; 3LBD; 1 FTD; 1 semantic
dementia; 1 traumatic brain injury-induced dementia);
56 MCI-MCI (stable); (p317)
Number included in analysis: 134
Conversion to AD dementia for CSF Abeta42:
Sensitivity 93%; Specificity 53% (p318)
TP=53; FP=36; FN=4; TN=41
Conversion to AD dementia for CSF Abeta42/Abeta40
ratio; Sensitivity 87%; Specificity 78% (p318)
TP=50; FP=17; FN=7; TN=60
Loss to follow-up: 3 participants died before completion
of 4 years follow-up and were excluded from the
analyses because their cognitive ability was uncertain
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Hertze 2010
Patient Selection
A. Risk of Bias
Patient Sampling
94 patients with AD, 166 patients with MCI and 29
patients with depressive disorder recruited from a
university hospital memory clinic and 38 healthy
controls. We only included data on performance of
the index test to discriminate between patients
with MCI who convert to dementia and those who
remained stable.
Patients with other causes of cognitive impairment
(subdural haematoma, brain tumour, CNS
infection,schizophrenia, major depressive episode,
or current alcohol abuse) were excluded. MCI
participants with signs of white matter changes or
silent brain infarctions were not excluded, because
these changes are common in the elderly. MCI
participants with moderate depression and low
plasma concentrations of vitamin B12 or folate
were also not excluded.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
166 MCI participants diagnosed by the
Petersen 2004 criteria at baseline. Baseline
demographic data reported for 159
participants.
Gender: 65 men; 91women. MCI-MCI: 36 M;
46 F; MCI-AD: 18 M; 34 F; MCI-other: 14 M;
11 F
Age: mean 72 (7.3) years; MCI-MCI 69 (7.5)
years; MCI-AD 76 (7.8) years; MCI-other 72
(6.7) years
APOE ε4 carrier: 63; MCI-MCI 37/82 (45%);
MCI-AD 40/52 (77%); MCI-other 12/25 (48%)
MMSE: MCI-MCI: 28.3 (1.3); MCI-MD: 26.1
(1.6); MCI-AD 26.9 (2.0)
Setting: secondary care, outpatients - memory
clinic, Malmo University hospital, Sweden
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
CSF: Abeta42
CSF was collected in polypropylene tubes, stored at −80C and analysed after the clinical follow-up of
the study was completed. The procedure followed The Alzheimer’s Association Flow Chart for LP and
CSF sample processing (Blennow 2010). Abeta 42 and Abeta 40 levels were analysed using an
electrochemiluminescence method, using the MS6000 Human Abeta 3-Plex Ultra-sensitive kit (Meso
Scale Discovery, USA).
Threshold(s): 209 pg/ml determined at baseline and based on previously established cut-off levels in
AD, control and depression (Fig.3B, p1125)
At baseline MCI:101 with 'normal CSF abeta42 level'; with 'abnormal CSF abeta42 level'
It was unclear whether those interpreting the index test results were aware of the outcome of clinical
follow-up
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease
dementia or other forms of dementia
Reference standards: NINCDS-ADRDA
and DSM-III-R criteria for Alzheimer's
disease dementia; NINDS-AREN ICD and
DSM-III-R criteria for vascular dementia;
McKeith criteria for LB dementia
The index test was conducted using stored
samples, after clinical follow-up
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: 4.7 years (range 3.0-7.2)
At follow-up: 166 MCI: 81 MCI-converters (55
MCI-AD; 26 MCI-other); 85 MCI-MCI (p1125)
Number included in analyses=159: 77 MCI-
converters (52 MCI-AD; 25 MCI-other); 82 MCI-
MC
TP=47; FP=32; FN=5; TN=75 for conversion to
Alzheimer's disease dementia (Fig 1B, p1125)
TP=11; FP=68; FN=14; TN=66 for conversion to
non-Alzheimer's disease dementia (Fig 1B, p1125)
TP=58; FP=21; FN=19; TN=61 for conversion to
all dementias (Fig 1B, p1125)
Loss to follow-up: In 7 MCI participants xMAP
analysis resulted in technical errors and this
sample was excluded from the study (p1121)
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Low risk
Notes
Notes The trial investigators contacted; they confirmed that their study is not a multiple
publication to Hansson 2007; email from Dr Hertze on 7/1/13
 
Herukka 2007
Patient Selection
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A. Risk of Bias
Patient Sampling
Participants examined in a university hospital neurological
department,or from an ongoing population-based study were
included if they agreed to a lumbar puncture for research
purposes and had a baseline diagnosis of MCI; 79
participants met these criteria. 60 controls (who were referred
to the neurological department for different symptoms, or who
were included in the population-based study and had
depression with normal performance inneuropsychological
tests) were also included. We only included data on
performance of the index test to discriminate between
patients with MCI who convert to dementia and those who
remained stable.
No exclusion criteria were specified
Was a consecutive or random sample of patients enrolled? No
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
79 MCI participants diagnosed by the
CDR=0.5 criteria at baseline.
Gender: 33 men; 46 women
Age:70.56 years; MCI-MCI: 69.46֨±8.14; MCI-
progressive: 71.76±6.71
APOE ε4 carrier: 41; MCI-MCI: 15/45 (33.3%);
MCI-progressive: 26/33 (78.8%)
MMSE: MCI-MCI: 24.09±2.49; MCI-
progressive: 23.91±2.69
Setting: Secondary care, inpatients -
Neurological department, Kuopio University
Hospital, Finland
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
CSF Abeta42
The CSF samples were collected by LP during the baseline visit. The samples were stored in
polypropylene tubes at -70°C until analysis. CSF Abeta 42 analysed using a commercial ELISA
(Innogenetics, Belgium)
Threshold(s): 450 pg/ml; determined at baseline using previously published cut off values from the
ROC analysis (Herruka 2005)
At baseline 79 MCI: 48 with 'normal CSF Abeta42 level'; 31 with 'abnormal CSF Abeta42 level'
Index test was conducted before clinical follow-up
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease dementia
or other forms of dementia
Reference standard: NINCDS-ADRDA for
Alzheimer's disease dementia; DSM-IV-R criteria
for other dementia
Diagnosis of dementia was done independently
and blinded to CSF biomarker results
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: mean 3.52±1.95 years in
MCI-converters; mean 4.56±3.09 years in MCI-
stable
At follow-up:79 MCI: 33 MCI-converters (27
MCI-AD; 1 MCI-SVD; 5 MCI-MD); 46 MCI-MCI
(p509)
Number included in analyses=79: 48 with
'normal CSF Abeta amyloid level': 35 MCI-MCI;
13 MCI-converters; 31 with 'abnormal CSF
Abeta42 amyloid level': 11 MCI-MCI; 20 MCI-
converters (Fig 1, p510)
TP=20, FP=11, FN=13, TN=35 (Fig 1, p510)
(for all dementias)
Loss to follow-up: CSF marker and follow-up
data appeared to have been available for all
participants
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Kester 2011
Patient Selection
A. Risk of Bias
Patient Sampling
153 MCI participants with available CSF
results and APOE ε4 genotyping were
recruited from the memory clinic in the
period between January 2001 and May
2008. 107 of those 153 patients had follow-
up data available.
No exclusion criteria were reported
Was a consecutive or random sample of patients enrolled? No
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
153 MCI participants diagnosed by the
Petersen 1999 criteria at baseline. Baseline
demographic data reported for 100
participants, who were included in the analysis.
Gender: 59 men; 41 women. MCI-MCI: 38 M;
20 F; MCI-AD: 21 M; 21 F
Age: 67±9 years MCI-MCI; 69±7 years MCI-
AD
APOE ε4 carrier: 27/58 MCI-MCI; 30/42 MCI-
AD
MMSE: 27±2 MCI-MCI; 26±3 MCI-AD
Setting: secondary care, outpatients - memory
clinic, Amsterdam, Netherlands
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
CSF: Abeta42
CSF was obtained by lumbar puncture between the L3/L4 and L4/L5 intervertebral space and
collected in 10ml polypropylene tubes. CSF samples were processed within 2 hours (centrifuged at
1800 g for 10 min at 4°C and stored at -80°C in polypropylene tubes until analysis). Abeta42 was
measured using a commercial sandwich ELISA (Innotest).
Threshold(s): <495 pg/ml abnormal level; determined at baseline and based on published data (Table
1, p1374)
Index test was conducted before clinical follow-up
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease
dementia or other forms of dementia
Reference standard: NINCDS-ADRDA
criteria Alzheimer's disease dementia;
Neary 1998 criteria; Roman 1993 criteria;
McKeith 2005 criteria
Unclear whether clinicians conducting
follow-up were aware of CSF biomarker
results
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Duration of follow-up: median 18 months (IQR
13-24); for MCI-converters the median was 17
months (IQR 13-24); for MCI-stable the median was
18 months (IQR 12-25)
At follow-up: 107 MCI: 49 MCI-converters (42 MCI-
AD; 3 MCI-FTD, 2 MCI-VD; 1 MCI-LBD; 1 MCI-
dementia due to hydrocephalus); 58 MCI-MCI
(p1373)
Number included in analyses=100: 52 with 'normal'
CSF Abeta42 level: 42 MCI-MCI, 10 MCI-AD; 48
'abnormal' CSF Abeta42 level: 16 MCI-MCI, 32 MCI-
AD (Table 1, p1374)
TP=32; FP=16; FN=10; TN=42
Loss to follow-up: 53: 7 'MCI participants who
converted to other dementias were excluded from the
analysis; 46 participants did not have follow-up data;
no further information
Was there an appropriate interval between index test and reference
standard? No
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? High risk
Notes
Notes  
Monge-Argiles 2011
Patient Selection
A. Risk of Bias
Patient Sampling
37 patients with MCI, attending the cognitive
deterioration out-patients clinic of a general
hospital and 24 control subjects without
subjective memory loss or known cognitive
deterioration. We only included data on
performance of the index test to discriminate
between patients with MCI who convert to
dementia and those who remained stable.
Participants with dementia or other
neurological, psychiatric or medical disease
which could provoke cognitive deterioration,
anti-coagulant therapy, failure to obtain
informed consent, or a Yesavage depression
scale score >5 were excluded
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
37 participants diagnosed by the Petersen
2006 criteria at baseline
Gender: 13 men; 24 women; MCI-MCI:
11M, 15F; MCI-AD: 2M, 9F
Age: mean 73.43±6.63 years
APOE ε4 carrier: not reported
MMSE: mean 25±2.4; MCI-AD: mean
23±1.2
Time between MCI diagnosis and study
entry (months): 1-12 (n=5); 13-24 (n=9);
25-36 (n=1); 37-48 (n=3); 49-60 (n=6); >61:
2
Setting: secondary care, outpatients -
General Hospital, Spain
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
CSF: Abeta42
The LP was performed by their own neurologist with a 20X3.5 gauge needle. CSF was collected in
standard tubes and centrifuged if little sanguinolent, before being frozen. CSF samples with obvious
blood were discarded. Abeta 1–42 was analysed using xMAP Luminex technology and INNO-BIA
Alzbio3 reagents (Innogenetics, Belgium).
Threshold(s): 320 pg/ml; determined at follow-up and derived from ROC analysis of controls and the
whole MCI population (Table 6, p 990)
At baseline 37 MCI: 18 with 'normal CSF Abeta amyloid level'; 19 with 'abnormal CSF Abeta amyloid
level'
Index test was conducted before clinical follow-up
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease
dementia
Reference standard: NINCDS-ADRDA
criteria
Unclear whether clinicians conducting
follow-up were aware of CSF biomarker
results
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
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Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: 6 months
At follow-up: 37MCI: 11 MCI-AD; 26 MCI-MCI
(Table 1, p989); Sensitivity 82%; Specificity
62% (Table 6, p990)
Number included in analyses=37 MCI: 18 with
'normal CSF Abeta amyloid level': 16 MCI-
MCI; 2 MCI-converters; 19 with 'abnormal
CSF Abeta amyloid level': 10 MCI-MCI; 9
MCI-converters
TP=9, FP=10, FN=2, TN=16
Loss to follow-up: CSF marker and follow-up
data appeared to have been available for all
participants
Was there an appropriate interval between index test and reference
standard? No
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? High risk
Notes
Notes  
Papaliagkas 2009
Patient Selection
A. Risk of Bias
Patient Sampling
53 patients with MCI, selected from a
hospital memory and dementia clinic
No exclusion criteria were reported
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
53 MCI participants diagnosed by the Petersen
1999 criteria at baseline
Gender: 22 men; 31 women
Age: 67.2 years MCI-MCI; 73.0 years MCI-AD
APOE ε4 carrier: not reported
MMSE: 28 (27-29) MCI-MCI; 26 (24-28) MCI-AD
Setting: secondary care, outpatients - Memory
and Dementia clinic, 'G. Papanikolaou' Hospital,
Thessaloniki, Greece
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
CSF: Abeta42
LP through L3/L4 or L4/L5 interspace. All CSF samples were stored at –80 ° C until analysis. Abeta
1-42 analysis used a commercial sandwich ELISA (Innotest-amyloid (1–42), Innogenetics, Belgium).
Threshold(s): 472 pg/ml; determined at follow-up nd derived from ROC analysis (p32)
At baseline 53 MCI: 37 with 'normal Abeta42 level'; 16 with 'abnormal CSF Abeta1-42 level'
Index test was conducted before clinical follow-up
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All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease
dementia
Reference standard: the criteria used to
define progression to Alzheimer's disease
dementia were not clearly defined
Unclear whether clinicians conducting
follow-up were aware of CSF biomarker
results
Is the reference standards likely to correctly classify the target condition? Unclear
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? High
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: 11 months
At follow-up: 53 MCI: 5 MCI-AD; 48 MCI-MCI
(Table 1, p32; Fig 2, p33)
Number included in analyses=53; Sensitivity
100%; Specificity 77.1% (p32)
TP=5, FP=11, FN=0, TN=37
Loss to follow-up: CSF marker and follow-up
data appeared to have been available for all
participants
Was there an appropriate interval between index test and reference
standard? No
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? High risk
Notes
Notes Relevant clinical information? Unclear from text
 
Parnetti 2006
Patient Selection
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A. Risk of Bias
Patient Sampling
273 consecutive patients with a suspected cognitive
impairment were referred by GPs or other specialists to
an out-patient memory clinic during the period January
2001 to June 2003.
Exclusion criteria: patients fulfilling clinical and
neuroradiological criteria for subcortical ischaemic
vascular dementia were excluded; patients with
secondary cases of cognitive impairment were also
excluded. No further exclusion criteria were defined
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
55 MCI participants were diagnosed by the
Petersen 1999 criteria at baseline
Gender: not reported
Age: not reported
APOE ε4 carrier: not reported
MMSE: not reported
Setting: secondary care, memory clinic,
Perugia, Italy
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
CSF: Abeta42
CSF was centrifuged for 10 min at 4000 g, then stored at -80ºC until analysis. Abeta 42 was assessed
using a commercial ELISA (Innotest b-amyloid 1–42, Innogenetics).
Threshold(s): 500 pg/l; determined at baseline and based on published criteria (p130)
At baseline 55 participants: 47 with 'normal CSF Abeta1-42 level'; 8 with 'abnormal CSF Abeta1-42
level'
Index test was conducted before clinical follow-up
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease
dementia
Reference standard: NINCDS-ADRDA
criteria
Unclear whether clinicians conducting
follow-up were aware of CSF biomarker
results
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: 12 months
At follow-up: 55 MCI: 11 MCI-AD; 33 MCI-MCI
(stable); 11 participants showed a further
progression of cognitive impairment, still not
fulfilling the diagnostic criteria for dementia
(p130)
Number included in analyses=55: 11 MCI-ADD;
44 MCI-non-converters; Sensitivity 36%;
Specificity 91% (p131)
TP=4, FP=4; FN=7; TN=40
Loss to follow-up: CSF marker and follow-up
data appeared to have been available for all
participants
Was there an appropriate interval between index test and reference
standard? No
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? High risk
Notes
Notes  
Shaw 2009
Patient Selection
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A. Risk of Bias
Patient Sampling
819 Participants from the ADNI longitudinal
neuroimaging study who met the criteria for initial
diagnosis of amnestic MCI (397), probable AD (193), or
normal cognition (229). The ADNI is a large multicenter,
longitudinal neuroimaging study; participants have been
recruited from over 50 sites across the United States
and Canada.
Baseline CSF samples were available for 416
participants (200 with amnestic MCI, 102 with probable
AD and 114 with normal cognition). We only included
data on performance of the index test to discriminate
between patients with MCI who convert to dementia
and those who remained stable.
Data from normal controls were used, along with data
from samples from ADNI-independent, autopsy-
confirmed AD cases, to derive cut-off values for
biomarkers.
Exclusion criteria: any serious neurological disease
other than possible AD, history of brain lesions of head
trauma, use of psychoactive medication
(antidepressants, neuroleptics, chronic anxiolytics, or
sedative hypnotics)
Was a consecutive or random sample of patients enrolled? No
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
200 participants with baseline CSF sample,
diagnosed with MCI condition if: i) a Mini-
Mental State Examination score was 24 to 30;
ii) a Memory Box score was at least 0.5.
Baseline demographic data reported for 196
participants. Manuscript cited the full ADNI
protocol available on line and this confirmed
use of Petersen Criteria components as
inclusion for their amnestic MCI group.
Gender: 131men / 65 women
Age: 75 years MCI-MCI; 76 years MCI-ADD
APOE ε4 carrier: 106
MMSE: 26.9±1.8
Participants fulfilling the criteria for the clinical
diagnosis of MCI
Setting: mixed setting; multicentre study - USA
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
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Index tests
CSF: Abeta42
CSF samples were obtained in the morning, following overnight fast. Samples were transferred into
polypropylene transfer tubes and frozen on dry ice within 1 hour of collection, and shipped overnight to
the ADNI Biomarker Core laboratory at the University of Pennsylvania Medical Center. Samples were
then stored in polypropylene vials at -80°C. Abeta 1-42 was analysed using the multiplex xMAP
Luminex platform (Luminex, Texas) with immunoassay kit-based reagents (Innogenetics, Belgium).
Threshold: 192 pg/ml determined at baseline and derived from ROC analysis of the ADNI normal
cognition subjects and the ADNI-independent autopsy-confirmed AD samples (fig 1, p407)
At baseline196 MCI: 51 with 'normal CSF Abeta1-42 level'; 145 with 'abnormal CSF Abeta1-42 level
Index test was conducted before clinical follow-up
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease
dementia
Reference standard: NINCDS-ADRDA (all
MCI-ADD participants met criteria for
probable AD: MMSE score was between 20
and 26, a global Clinical Dementia Rating
was 0.5 or 1, a sum-of-boxes Clinical
Dementia Rating was 1.0 to 9.0)
Unclear whether clinicians conducting
follow-up were aware of CSF biomarker
results
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: 12 months
At follow-up: 196 MCI: 37 MCI-AD; 156 MCI-MCI;
3 MCI-normal (Table 2, p408)
Number included in analyses=196: 37 MCI-AD;
159 MCI-non-converters
TP=32, FP=113, FN=5, TN=46 (Fig 1B; Fig 3)
Loss to follow-up: 4 participants; no reasons were
reported
Was there an appropriate interval between index test and reference
standard? No
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? High risk
DTA1 Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other demen...
43 / 79
Notes
Notes  
Vos 2013
Patient Selection
A. Risk of Bias
Patient Sampling
399 participants with aMCI and 226
participants with naMCI from the DESCRIPA
cohort and Alzheimer Center of the VU
University medical center (VUmc).
DESCRIPA is a European multicentre study
performed in a memory-clinic setting and
enrolled subjects between 2003 and 2005.11
For this study, 431 eligible subjects were
selected from 16 participating centers in
which CSF was collected, MRI was
performed, or APOE genotype was
determined. The VUmc center was one of
the DESCRIPA centers and contributed an
additional sample of 194 subjects that were
seen outside the DESCRIPA inclusion period
with data on CSF, MRI, or APOE measures.
No differences in biomarkers were found
between subjects from the VUmc center in
the DESCRIPA study and those from the
additional VUmc sample.
Exclusion criteria were diagnosis of
dementia at baseline or any other somatic,
psychiatric or neurological disorder that
might have caused the cognitive impairment
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
625 MCI participants diagnosed by Petersen
2004 criteria at baseline. 231 of those
participants had CSF Abeta1-42 assessment.
214 subjects with CSF data had a least one
follow-up assessment. Baseline demographic
data reported on all 625 participants.
Gender: 270 men; 335 women
Age: 70.7±7.6 years naMCI; 70.7±7.8 aMCI
MMSE: 27.5±2.1 naMCI; 26.5±2.5 aMCI
Setting: secondary care - European
multicentre memory clinics
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
DTA1 Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other demen...
44 / 79
Index tests
CSF Abeta1-42
CSF was collected by lumbar puncture, centrifuged, and stored at -80°C in polypropylene tubes. Three
samples were thawed twice but analyses without these samples revealed similar results. CSF
Abeta1-42 and total tau (t-tau) were measured by experienced technicians using commercially
available sandwich ELISAs (Innotest Abeta-amyloid 1-42; Innotest hTAU-Ag; Innogenetics, Ghent,
Belgium), specially constructed to measure Abeta-amyloid 1-42 and t-tau, at the lab in Gothenburg for
the DESCRIPA cohort and in Amsterdam for the additional subjects of the VUmc cohort. We corrected
for interlaboratory ELISA differences by analyzing 33 samples at both labs and we adjusted VUmc
values to those of DESCRIPA using the following formula: Gothenborg=(SD Gothenborg/SD
VUmc)*VUmc+average Gothenborg– ((SD Gothenborg /SD VUmc)*average VUmc).
Threshold: <500 pg/ml determined at baseline
and based on published criteria (Hulstaert 1999; Wolz 2010)
At baseline 214 MCI: 111 with 'normal CSF Abeta42 level'; 103 with 'abnormal CSF Abeta42 level'
Index test was conducted before follow-up
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease
dementia
Reference standard: DSM-IV criteria;
NINCDS-ADRDA criteria
Diagnosis of dementia was conducted
blinded to results of CSF biomarker
analysis (p8)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Duration of follow-up: mean 2.5 years (max
duration 5 years); follow-up was performed
annually
At baseline: 214
At follow-up: 214 MCI: 91 MCI-AD; 123 MCI-
MCI
Number included in analysis: 214 (with CSF
data who had a least one follow-up
assessment)
TP=62; FP=41; FN=29; TN=82 (from Dr Vos's
email)
Loss to follow-up: 17 (some participants
refused to participate or were untraceable or
died before follow-up)
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Low risk
Notes
Notes In press. The trial investigators contacted; they provided requested data tor the 2x2
table to be completed; email from Dr Vos on 8/2/13
 
Zetterberg 2003
Patient Selection
A. Risk of Bias
Patient Sampling
53 Consecutive patients from a speciality
referral university hospital memory clinic
No exclusion criteria were reported
The study aimed to evaluate a combination of
biomarkers for identifying incipient AD in MCI
patients
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
53 participants diagnosed by the Petersen
1999 criteria at baseline
Gender: not reported
Age: range = 50-83 years
APOE ε4 carrier: not reported
MMSE: mean 27±1.7 participants fulfilling
the criteria for the clinical diagnosis of MCI
Setting: secondary care, outpatients -
memory clinic, Huddinge, Sweden
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
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Index tests
CSF Abeta42
CSF analysis methods were not described, but other publications were cited (Hulsteart 1999;
Vanmechelen 2000))
Threshold(s): 'the optimal cut-point for Abeta42 alone was 532 ng/L, defined using the Youden index'
(email from Dr Zetterberg on 6/12/10)
CSF analysis methods were not described, but other publications were cited (refs 13 and 19)
The optimal cut-off for Abeta 42 was reported as < 400 pg/mL, derived from ROC analysis
Index test was conducted before clinical follow-up
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease dementia
or other forms of dementia
Reference standard: DSM-IV criteria
'Diagnoses were made independently of CSF
markers' (p67)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration: 20±10 months
At follow-up: 53 MCI; 22 MCI-AD; 10 MCI-other
dementias (3 VD, 2 LBD, 1 FTD, 1 normal pressure
hydrocephalus,1 corticobasal degeneration, 1 PD with
dementia and 1 depressive pseudodementia); 21 MCI-
MCI (p67-68)
Sensitivity 68; Specificity 61%
Number included in analyses=53; Sensitivity=68;
Specificity=61% (from Dr Zetterberg's email)
TP=15; FP=12; FN=7; TN=19 (from Dr Zetterberg's
email)
Loss to follow-up: follow-up data were reported for all
participants; biomarker data were only reported as mean
and SD
Was there an appropriate interval between index test and
reference standard? No
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? High risk
Notes
DTA1 Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other demen...
47 / 79
Notes The trial investigators contacted; they provided requested data tor the 2x2 table to be
completed (email from Dr Zetterberg on 2/12/10). There is no overlap between
Zetterberg 2003 and Bloom 2009 studies regarding the participants (email from Dr
Zetterberg on 4/10/13)
 
Footnotes
Characteristics of excluded studies 
Andersson 2007
Reason for exclusion Study design: no threshold used. The trial investigators contacted. No reply
 
Andersson 2008
Reason for exclusion Study design: no threshold used. The trial investigators contacted. No reply
 
Andreasen 2001
Reason for exclusion Study design: threshold based on combined biomarkers: Abeta and tau
 
Andreasen 2003
Reason for exclusion Study design: only AD progressors used in analysis
 
Bertens 2012
Reason for exclusion Target condition: not looking at MCI conversion to dementia (changes in Abeta42
levels measured over time)
 
Blasko 2008
Reason for exclusion Study design: no threshold used. The trial investigators contacted. No reply
 
Bouwman 2007
Reason for exclusion Insufficient data to complete 2x2 table. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared
 
de Leon 2002
Reason for exclusion Study design: no threshold used
 
de Leon 2006
Reason for exclusion Insufficient data to complete 2x2 table. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared
 
Ellis 2012
Reason for exclusion Study design: no threshold used
 
Fagan 2007
Reason for exclusion Target condition: not looking at MCI conversion to dementia
 
Forlenza 2010
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Reason for exclusion Insufficient data to complete 2x2 table. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared
 
Gustafson 2007
Reason for exclusion Population: unclear MCI diagnostic criteria used at baseline
 
Hansson 2010
Reason for exclusion Insufficient data to complete 2x2 table. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared
 
Ivanoiu 2005
Reason for exclusion Insufficient data to complete 2x2 table. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared
 
Johansson 2011
Reason for exclusion Index test: CSF was performed at follow-up. The trial investigators contacted
 
Li 2007
Reason for exclusion Target condition: not looking at conversion to dementia in the MCI sample included
 
Lopez 2008
Reason for exclusion Study design: no threshold used. The trial investigators contacted
 
Maruyama 2001
Reason for exclusion Study design: analysis based on those who converted and distinguishing healthy
controls from MCI
 
Mayeux 2003
Reason for exclusion Target condition: not looking at conversion to dementia in the MCI sample included
 
Parnetti 2012
Reason for exclusion Insufficient data to complete 2x2 table. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared
 
Perneczky 2011
Reason for exclusion Study design: no threshold used. The trial investigators contacted
 
Pesaresi 2006
Reason for exclusion Population: unclear MCI diagnostic criteria used at baseline
 
Ramakers 2012
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Reason for exclusion Target condition: not looking at MCI conversion to dementia; the focus of the study is
the association between abnormal CSF biomarkers' concentration and
neuropsychological decline (e.g. in memory performances, excecutive functioning,
etc.)
 
Riemenschneider 2002
Reason for exclusion Index test: combined CSF Abeta42 and tau proteins
 
Seppala 2010
Reason for exclusion Study design: no threshold used
 
Skoog 2003
Reason for exclusion Study design: no threshold used
 
Snider 2009
Reason for exclusion Study design: no threshold used
 
Sobow 2007
Reason for exclusion Study design: no threshold used. The trial investigators contacted. No reply
 
Storace 2010
Reason for exclusion Insufficient data to complete 2x2 table. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared
 
Uspenskaya 2010
Reason for exclusion Insufficient data to complete 2x2 table. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared
 
Vanderstichele 2005a
Reason for exclusion Study design: no threshold used
 
Visser 2009
Reason for exclusion Index test: looking at the tau/Abeta ratio
 
Vos 2011
Reason for exclusion Index test: looking at the tau/Abeta ratio
 
Vos 2012
Reason for exclusion Index test: looking at the tau/Abeta ratio
 
Vos 2012a
Reason for exclusion Index test: looking at the tau/Abeta ratio
 
Wahlund 2003
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Reason for exclusion Study design: no threshold used
 
Zetterberg 2007
Reason for exclusion Study design: no threshold used and looking at intra-individual variations in biomarkers
over time
 
Footnotes
Characteristics of studies awaiting classification 
Footnotes
Characteristics of ongoing studies 
Rainero 2012
Study name Predictive value of CSF biomarkers for Alzheimer's disease in cohort of patients with
mild cognitive impairment
 
Target condition and reference
standard(s)
Alzheimer's disease dementia
 
Index and comparator tests CSF Aß 42
 
Starting date Not stated in the conference abstract
 
Contact information irainero@molinette.piemonte.it
 
Notes An update at the 2013 AAN meeting in San Diego" (email from Prof Rainero on 5/1/13)
 
Footnotes
Summary of results tables
1 Performance of plasma and CSF amyloid biomarkers
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What is the diagnostic accuracy of plasma and CSF amyloid biomarker levels for detecting Alzheimer's disease pathology in
patients with mild cognitive impairment (MCI), and identifying those MCI participants who would convert to Alzheimers
disease dementia or other forms of dementia over time
Patient
population
Participants diagnosed with MCI at baseline using any of the Petersen criteria or CDR = 0.5 or any
16 definitions included by Matthews (Matthews 2008)
Prior testing The only testing prior to performing the plasma and CSF biomarkers was the application of diagnostic criteria
for identifying participants with MCI
Settings Participants were recruited from i) secondary care – outpatient clinic (n = 12); ii) secondary care – inpatients (n
= 2); iii) community care (n = 2) and mixed setting (n = 1)
Index tests Plasma or CSF Aß 42, Aß 40, or Aß 42/Aß 40 ratio
Reference
standard
NINCDS-ADRDA or DSM or ICD criteria for Alzheimer's disease dementia; McKeith criteria for Lewy body
dementia; Lund criteria for frontotemporal dementia; and NINDS AIREN criteria for vascular dementia
Target
condition
Alzheimer’s disease dementia or any other form of dementia
Included
studies
17 studies (2228 participants) of prospectively well defined cohorts with any accepted definition of MCI were
included
Quality
concerns
Patient selection and conduct of the index and reference standard were poorly reported. Applicability concerns
were generally low. Regarding the inclusion criteria set in the review, each included study did match the
review question: 'Could Plasma and CSF Aß biomarkers identify those MCI participant with Alzheimer’s
disease pathology at baseline who would convert clinically to dementia at follow up?' However, due to limited
number of included studies and levels of heterogeneity it is difficult to determine to what extent the findings
from a meta-analysis can be applied to clinical practice.
Limitations Limited investigation of heterogeneity due to insufficient number of studies. There was a lack of common
thresholds and poor reporting of thresholds.
Test StudiesCases/participants Median specificity
from included
studies
 
Sensitivity 
(95% CI)1 at
median
specificity 
Consequences in a cohort of 100
Median percentage
converting (range) 2
Missed
cases3
Overdiagnosed
3
Alzheimer's disease dementia
CSF
Aß
42
14 436/1349 64 81 (72, 87) 38 (9 to 56) 7 22
All forms of dementia
CSF
Aß
42
4 188/464 75 63 (22, 91) 45 (27 to 53) 17 14
Non-Alzheimer's disease dementia
CSF
Aß
42
3 61/385 65 No meta-analysis  
16 (15 to 19)
   
Investigation of heterogeneity: the planned investigations were not possible due to the limited number of studies available
for each analysis. We were unable to investigate the effect of duration of follow up due to substantial variation in length and
reporting.
Conclusions: from our review, abnormally low CSF Aß levels has very little diagnostic benefit with likelihood ratios
suggesting only marginal clinical utility. The quality of reports was also poor, and thresholds and length of follow up were
inconsistent. We conclude that when applied to a population of patients with MCI, CSF Aß levels cannot be recommended
as an accurate test for Alzheimer's disease.
 
Footnotes
1 Meta-analytic estimate of sensitivity derived from the HSROC model at a the median value of specificity computed from the
included studies. Summary estimates of sensitivity and specificity were not computed because the studies that contributed to
the estimation of the summary ROC curve used various thresholds.
2 
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The median percentage converting and range were computed using all the studies included in the analysis for each target
condition.
3 Missed and overdiagnosed numbers were computed using the median percentage converting for each target condition.
Additional tables 
1 Sensitivity of CSF Aß42 at fixed values of specificity for conversion to Alzheimer's dementia and all forms of
dementia
Statistic Fixed value of specificity % Estimated sensitivity % (95% CI)
Conversion to Alzheimer's dementia (n = 14; cases = 436 ; non-cases = 913)
Lower quartile 57 84 (76, 90)
Median 64 81 (72, 87)
Upper quartile 72 75 (64, 83)
Conversion to Alzheimer's dementia sensitivity analyses excluding Kester 2011* (n = 13; cases = 394 ; non-cases = 855)
Median 62 82 (73, 88)
Conversion to Alzheimer's dementia sensitivity analyses excluding studies at high or unclear risk of bias for patient selection
domain (n = 6; cases = 100 ; non-cases = 299) 
Median 61 78 (55, 91)
Conversion to Alzheimer's dementia sensitivity analyses excluding studies at high risk of bias for index test domain (n = 6;
cases = 255 ; non-cases = 534)
Median 68 76 (60, 87)
Conversion to Alzheimer's dementia sensitivity analyses excluding 3 outliers (n = 11; cases = 374 ; non-cases = 696) 
Median 67 82 (69, 90)
All forms of dementia (n = 4; cases = 188; non-cases = 276)
Median 75 63 (22, 91)
Footnotes
* The study did not consider a sample of MCI non-AD converters in their analysis but excluded them.
The middle 50% of specificities from the included studies were between the lower and upper quartile, i.e. the interquartile
range.
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Data and analyses 
Data tables by test
Test StudiesParticipants
1 CSF Abeta42 AD 14 1349
2 CSF Abeta 42 All dementia 4 464
3 CSF Abeta 42 non-AD 3 385
4 CSF Abeta42/Abeta40 AD 2 199
5 Plasma Abeta 42 AD 1 565
6 Plasma Abeta42/Abeta40 AD1 562
Figures
Figure 1
DTA1 Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other demen...
62 / 79
Caption
Flow of studies through the screening process.
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Figure 2
Caption
Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study.
Figure 3
Caption
Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages
across included studies.
Figure 4 (Analysis 1) 
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Caption
Forest plot of study results of cerebrospinal amyloid beta 42 for detection of Alzheimer's disease dementia.
Figure 5 (Analysis 1) 
Caption
Summary ROC plot for cerebrospinal amyloid beta 42 for detection of Alzheimer's disease dementia. Study estimates of
sensitivity and specificity are shown with the summary ROC curve.
Figure 6 (Analysis 2) 
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Caption
Forest plot of study results of cerebrospinal amyloid beta 42 for detection of all forms of dementia.
Figure 7 (Analysis 2) 
Caption
Summary ROC plot for cerebrospinal amyloid beta 42 for detection of all forms of dementia. Study estimates of sensitivity
and specificity (with 95% confidence intervals) are shown with the summary ROC curve.
Figure 8 (Analysis 3) 
Caption
Forest plot of study results of cerebrospinal amyloid beta 42 for detection of non-Alzheimer's disease dementia.
Figure 9 (Analysis 3) 
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Caption
Study estimates of sensitivity and specificity with 95% confidence intervals plotted in ROC space for cerebrospinal amyloid
beta 42 for the detection of non-Alzheimer's disease dementia.
Figure 10 (Analysis 4) 
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Caption
Summary ROC plot for cerebrospinal amyloid beta 42 for detection of Alzheimer's disease dementia. Study estimates of
sensitivity and specificity (with 95% confidence intervals) and summary ROC curves are shown according to whether or not
studies pre-specified the threshold for determining test positivity.
Figure 11
DTA1 Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other demen...
68 / 79
Caption
Pre- and post- tests probabilities of Alzheimer's dementia using low CSF amyloid beta 42 as a diagnostic test.
Sources of support 
Internal sources
No sources of support provided
External sources
No sources of support provided
Feedback 
Appendices 
1 Search strategies and sources searched
 
Source
Search strategy Hits
retrieved
1. MEDLINE In-process
and other non-indexed
citations and MEDLINE
1950-present [Searched
most recently on 3
December 2012 (OvidSP)]
 
1. exp Dementia/
2. Cognition Disorders/
3. exp Neurofibrils/
4. Neurofilament Proteins/
5. Senile Plaques/
6. Neuropil Threads/
7. (alzheimer$ or dement$).ti,ab.
 
Nov 2009:
8424
Jun 2011:
1479
Jan 2012:
601
Dec 2012:
1051
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8. ((cognit$ or memory or cerebr$ or mental$) adj3 (declin$ or impair$ or los$ or
deteriorat$ or degenerat$ or complain$ or disturb$ or disorder$)).ti,ab.
9. (forgetful$ or confused or confusion).ti,ab.
10. MCI.ti,ab.
11. ACMI.ti,ab.
12. ARCD.ti,ab.
13. SMC.ti,ab.
14. CIND.ti,ab.
15. BSF.ti,ab.
16. AAMI.ti,ab.
17. MD.ti,ab.
18. LCD.ti,ab.
19. QD.ti,ab.
20. AACD.ti,ab.
21. MNCD.ti,ab.
22. MCD.ti,ab.
23. (neurofibril$ adj3 tangle$).ti,ab.
24. (neurofilament adj3 protein$).ti,ab.
25. ((senile or amyloid or neuritic) adj3 plaque$).ti,ab.
26. (neuropil adj3 thread$).ti,ab.
27. or/1-26
28. exp Amyloid Beta-Protein/
29. Peptide Fragments/
30. ABPP.ti,ab.
31. APP.ti,ab.
32. beta?A4.ti,ab.
33. (beta adj3 A4).ti,ab.
34. Abeta$.ti,ab.
35. amyloid.ti,ab.
36. (amyloidogenic adj3 (peptide$ or protein$)).ti,ab.
37. (Innotest or Inno-bia or Alzbio3).ti,ab.
38. or/28-37
39. (cerebrospinal fluid$ or csf or spinal fluid$).ti,ab.
40. (blood or plasma).ti,ab.
41. Cerebrospinal Fluid/
42. Blood-Brain Barrier/
43. or/39-42
44. (cf or bl or di or du).fs.
45. 27 and 38 and (43 or 44)
46. exp Dementia/bl, cf [Blood, Cerebrospinal Fluid]
47. exp Dementia/di [Diagnosis]
48. 47 and 43
49. Cerebrospinal Fluid Proteins/
50. Biological Markers/cf, bl [Cerebrospinal Fluid, Blood]
51. or/49-50
52. 27 and 51
53. or/45-46,48,52
TOTAL:
11555
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54. exp Animals/ not Humans.sh.
55. 53 not 54
2. EMBASE
[Searched most recently:
December 2012 search:
197406-November week 4
2012 (OvidSP)]
 
1. exp dementia/
2. exp cognitive defect/ or exp mild cognitive impairment/
3. exp neurofilament/
4. exp neurofilament protein/
5. senile plaque/
6. neuropil thread/
7. (alzheimer$ or dement$).ti,ab.
8. ((cognit$ or memory or cerebr$ or mental$) adj3 (declin$ or impair$ or los$ or
deteriorat$ or degenerat$ or complain$ or disturb$ or disorder$)).ti,ab.
9. (forgetful$ or confused or confusion).ti,ab.
10. MCI.ti,ab.
11. ACMI.ti,ab.
12. ARCD.ti,ab.
13. SMC.ti,ab.
14. CIND.ti,ab.
15. BSF.ti,ab.
16. AAMI.ti,ab.
17. MD.ti,ab.
18. LCD.ti,ab.
19. QD.ti,ab.
20. AACD.ti,ab.
21. MNCD.ti,ab.
22. MCD.ti,ab.
23. ("N-MCI" or "A-MCI" or "M-MCI").ti,ab.
24. (neurofibril$ adj3 tangle$).ti,ab.
25. (neurofilament adj3 protein$).ti,ab.
26. ((senile or amyloid or neuritic) adj3 plaque$).ti,ab.
27. (neuropil adj3 thread$).ti,ab.
28. or/1-27
29. exp amyloid beta protein/
30. peptide fragment/
31. ABPP.ti,ab.
32. APP.ti,ab.
33. beta?A4.ti,ab.
34. Abeta$.ti,ab.
35. amyloid.ti,ab.
36. (beta adj3 A4).ti,ab.
37. (amyloidogenic adj3 (peptide$ or protein$)).ti,ab.
38. (Innotest or Inno-bia or Alzbio3).ti,ab.
39. or/29-38
40. 28 and 39
41. (cerebrospinal fluid$ or csf or spinal fluid$).ti,ab.
42. (blood or plasma).ti,ab.
43. cerebrospinal fluid/
 
Nov 2009:
5594
Jun 2011:
1739
Jan 2012:
1805
Dec 2012:
1629
TOTAL:
10767
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44. blood brain barrier/
45. or/41-44
46. 28 and 39 and 45
47. (cf or bl or di or du).fs.
48. or/45,47
49. 28 and 39 and 48
50. exp Dementia/di [Diagnosis]
51. 50 and 39
52. (bl or cf).fs.
53. 50 and (46 or 52)
54. protein cerebrospinal fluid level/
55. biological marker/ and (blood or plasma or CSF or "cerebrospinal fluid").ti,ab.
56. 54 or 55
57. 28 and 56
58. or/49,51,53,57
59. animal/
60. human/
61. 59 and 60
62. 59 not 61
63. 58 not 62
3. PsycINFO
[Searched most recently:
December 2012 search:
1806-November week 4
2012 (OvidSP)]
 
1. exp Dementia/
2. exp Cognitive Impairment/
3. Neurofibril*.mp.
4. exp Neurofibrillary Tangles/
5. Senile Plaques/
6. "neuropil threads".mp.
7. (alzheimer$ or dement$).ti,ab.
8. ((cognit$ or memory or cerebr$ or mental$) adj3 (declin$ or impair$ or los$ or
deteriorat$ or degenerat$ or complain$ or disturb$ or disorder$)).ti,ab.
9. (forgetful$ or confused or confusion).ti,ab.
10. MCI.ti,ab.
11. ACMI.ti,ab.
12. SMC.ti,ab.
13. CIND.ti,ab.
14. BSF.ti,ab.
15. AAMI.ti,ab.
16. MD.ti,ab.
17. LCD.ti,ab.
18. QD.ti,ab.
19. AACD.ti,ab.
20. MNCD.ti,ab.
21. MCD.ti,ab.
22. ("N-MCI" or "A-MCI" or "M-MCI").ti,ab.
23. (neurofibril$ adj3 tangle$).ti,ab.
24. ARCD.ti,ab.
25. (neurofilament adj3 protein$).ti,ab.
 
Nov 2009:
1848
Jun 2011:
620
Jan 2012:
446
Dec 2012:
382
TOTAL:
3296
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26. ((senile or amyloid or neuritic) adj3 plaque$).ti,ab.
27. (neuropil adj3 thread$).ti,ab.
28. or/1-27
29. exp Beta Amyloid/
30. exp Peptides/
31. ABPP.ti,ab.
32. APP.ti,ab.
33. beta?A4.ti,ab.
34. (beta adj3 A4).ti,ab.
35. Abeta$.ti,ab.
36. amyloid.ti,ab.
37. (amyloidogenic adj3 (peptide$ or protein$)).ti,ab.
38. (Innotest or Inno-bia or Alzbio3).ti,ab.
39. or/29-38
40. 28 and 39
41. (cerebrospinal fluid$ or csf or spinal fluid$).ti,ab.
42. (blood or plasma).ti,ab.
43. Cerebrospinal Fluid/
44. Blood Brain Barrier/
45. or/41-44
46. 28 and 39 and 45
47. Cerebrospinal Fluid/
48. exp Biological Markers/
49. 47 or 48
50. 28 and 49
51. 46 or 50
52. limit 51 to human
4. BIOSIS Previews (ISI
Web of Knowledge)
[searched most recently
on 3 December 2012]
 
Topic=(dementia OR neurofibrils OR neurofilament OR "senile plaques" OR neuropil
OR alzheimer* OR cognit* OR memory OR MCI OR ACMI OR SMC OR CIND OR
BSF OR AAMI OR AACD OR MNCD OR MCD OR nMCI OR aMCI OR mMCI) AND
Topic=("amyloid beta" OR "a beta" OR abeta OR amyloidogenic OR innotest OR
"inno-bia" OR alzbio3) AND Topic=("cerebrospinal fluid" OR "cerebro spinal fluid" OR
CSF OR blood OR plasma OR "blood-brain barrier")
 
Nov 2009:
1936
Jun 2011:
1321
Jan 2012:
743
Dec 2012:
551
TOTAL:
4551
5. Web of Science and
conference proceedings
(1945-present) [searched
most recently on 3
December 2012]
 
Topic=(dementia OR neurofibrils OR neurofilament OR "senile plaques" OR neuropil
OR alzheimer* OR cognit* OR memory OR MCI OR ACMI OR SMC OR CIND OR
BSF OR AAMI OR AACD OR MNCD OR MCD OR nMCI OR aMCI OR mMCI) AND
Topic=("amyloid beta" OR "a beta" OR abeta OR amyloidogenic OR innotest OR
"inno-bia" OR alzbio3) AND Topic=("cerebrospinal fluid" OR "cerebro spinal fluid" OR
CSF OR blood OR plasma OR "blood-brain barrier") AND Year
Published=(2011-2012)
Timespan=All Years. Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-
SSH.
Lemmatization=On
 
Nov 2009:
4998
Jun 2011:
1237
Jan 2012:
587
Dec 2012:
551
TOTAL:
7373
DTA1 Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other demen...
73 / 79
 
Source
Search strategy Hits
retrieved
6. LILACS (BIREME)
[searched most recently
on 3 December 2012]
 
“peptídeo beta-amilóide” OR “placas neuríticas” OR “emaranhados neurofibrilares”
OR “senile plaques” OR “β-amyloid” OR “beta-amiloide” OR “b-Amiloid” OR “ovillos
neurofibrilares” OR amilóide OR innotest OR “inno-bia” OR alzbio3 [Words] and CSF
OR LCR OR cefalorraquidiano OR “biological marker” OR “biological markers” OR
plasma OR plasmáticos OR plasmocitos [Words] and “comprometimento cognitivo
leve” OR “cognitive impairment” OR MCI OR Alzheimer OR Alzheimer’s OR AD OR
memory OR Memória OR memórias OR demências OR demência OR dementia
[Words]
 
Nov 2009:
0
Jun 2011:
0
Jan 2012:
6
Dec 2012:
(13-6)= 7
new
TOTAL:
13
Additional sources: Additional other review sources: MEDION database (searched 31 Jan for all dates);
Database of Abstracts of Reviews of Effects (searched Issue 1 of The Cochrane Library 2013); Health
Technology Assessments Database (searched Issue 1 of the Cochrane Library 2013); ARIF Aggressive
Research Intelligence Facility www.arif.bham.ac.uk [searched 3 Dec for all dates]
 
Dec 2012:
14
TOTAL:
14
TOTAL before de-duplication  
Nov 2009:
22800
Jun 2011:
6396
Jan 2012:
4188
Dec 2012:
4171
TOTAL:
37555
2 Assessment of methodological quality table QUADAS-2 tool
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DOMAIN PATIENT SELECTION   INDEX TEST  REFERENCE
STANDARD
FLOW AND TIMING 
Description Describe methods of
patient selection: Describe
included patients (prior
testing, presentation,
intended use of index test
and setting): 
Describe the index
test and how it was
conducted and
interpreted
Describe the
reference standard
and how it was
conducted and
interpreted
Describe any patients who did not
receive the index test(s) and/or
reference standard or who were
excluded from the 2x2 table (refer
to flow diagram): Describe the time
interval and any interventions
between index test(s) and
reference standard
Signalling
questions
(yes/no/unclear)
Was a consecutive or
random sample of patients
enrolled?
Were the index
test results
interpreted without
knowledge of the
results of the
reference
standard?
Is the reference
standard likely to
correctly classify the
target condition?
Was there an appropriate interval
between index test(s) and
reference standard?
Was a case-control design
avoided?
If a threshold was
used, was it pre-
specified?
Were the reference
standard results
interpreted without
knowledge of the
results of the index
test?
Did all patients receive a reference
standard?
Did the study avoid
inappropriate exclusions?
Did all patients receive the same
reference standard?
Were all patients included in the
analysis?
Risk of bias:
High/low/ unclear
Could the selection of
patients have introduced
bias?
Could the conduct
or interpretation of
the index test have
introduced
bias?      
Could the reference
standard, its conduct,
or its interpretation
have introduced
bias?
Could the patient flow have
introduced bias? 
Concerns
regarding
applicability:
High/low/ unclear
Are there concerns that the
included patients do not
match the review
question?
Are there concerns
that the index test,
its conduct, or
interpretation differ
from the review
question?
Are there concerns
that the target
condition as defined
by the reference
standard does not
match the review
question?
 
3 Anchoring statements for quality assessment of plasma and CSF Abeta biomarkers diagnostic studies
We provide some core anchoring statements for quality assessment of diagnostic test accuracy review of plasma and
CSF Aß levels in dementia. These statements are designed for use with the QUADAS-2 tool and are based on the
guidance for quality assessment of diagnostic test accuracy reviews of IQCODE in dementia (Quinn 2012). 
During a two day, multidisciplinary focus group and the piloting / validation of the  guidance, it was clear that certain issues
were key to assessing quality, while other issues were important to record but less important for assessing overall quality. To
assist, we describe a 'weighting' system.  Where an item is weighted “high risk” then that section of the QUADAS-2 results
table is likely to be scored as high risk of bias. For example in dementia diagnostic test accuracy studies, ensuring that
clinicians performing dementia assessment are blinded to results of index test is fundamental. If this blinding was not present
then the item on reference standard should be scored 'high risk of bias', regardless of the other contributory elements.
In assessing individual items, the score of unclear should only be given if there is genuine uncertainty. In these situations
review authors will contact the relevant study teams for additional information.
Anchoring statements to assist with assessment for risk of bias
Question Response
and
weighting
Explanation
Patient selection
DTA1 Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other demen...
75 / 79
 
Was the sampling method
appropriate?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Where sampling is used, the designs least likely to cause bias are
consecutive sampling or random sampling. Sampling that is based on
volunteers or selecting subjects from a clinic or research resource is prone
to bias.
Was a case-control or similar
design avoided?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Designs similar to case control that may introduce bias are those designs
where the study team deliberately increase or decrease the proportion of
subjects with the target condition, which may not be representative. Some
case control methods may already be excluded if they mix subjects from
various settings.
Are exclusion criteria described
and appropriate?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Study will be automatically graded unclear if exclusions are not detailed
(pending contact with study authors). Where exclusions are detailed, the
study will be graded as “low risk” if exclusions are felt to be appropriate by
the review authors. Certain exclusions common to many studies of dementia
are: medical instability; terminal disease; alcohol/substance misuse;
concomitant psychiatric diagnosis; other neurodegenerative condition.
Exclusions are not felt to be appropriate if ‘difficult to diagnose’ patients are
excluded. Post hoc and inappropriate exclusions will be labelled “high risk”
of bias.
Index test
Was plasma and CSF Abeta
biomarker
assessment/interpretation
performed without knowledge of
clinical dementia diagnosis?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Terms such as “blinded” or “independently and without knowledge of” are
sufficient and full details of the blinding procedure are not required.
Interpretation of the results of the index test may be influenced by
knowledge of the results of reference standard. If the index test is always
interpreted prior to the reference standard then the person interpreting the
index test cannot be aware of the results of the reference standard and so
this item could be rated as ‘yes’.
For certain index tests the result is objective and knowledge of reference
standard should not influence result, for example level of protein in
cerebrospinal fluid, in this instance the quality assessment may be “low risk”
even if blinding was not achieved.
Were plasma and CSF Abeta
biomarker thresholds pre-
specified?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
For scales and biomarkers there is often a reference point (in units or
categories) above which subjects are classified as “test positive”; this may
be referred to as threshold; clinical cut-off or dichotomisation point. A study
is classified high risk of bias if the authors define the optimal cut-off post-hoc
based on their own study data because selecting the threshold to maximise
sensitivity and / specificity may lead to overoptimistic measures of test
performance.
Certain papers may use an alternative methodology for analysis that does
not use thresholds and these papers should be classified as not applicable.
Reference standard
 
Is the assessment used for clinical
diagnosis of dementia acceptable?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Commonly used international criteria to assist with clinical diagnosis of
dementia include those detailed in DSM-IV and ICD-10. Criteria specific to
dementia subtypes include but are not limited to NINCDS-ADRDA criteria
for Alzheimer’s dementia; McKeith criteria for Lewy Body dementia; Lund
criteria for frontotemporal dementia; and the NINDS-AIREN criteria for
vascular dementia. Where the criteria used for assessment is not familiar to
the review authors or the Cochrane Dementia and Cognitive Improvement
group (‘unclear’) this item should be classified as “high risk of bias”.
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Was clinical assessment for
dementia performed without
knowledge of the plasma and CSF
Abeta biomarker biomarker?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Terms such as “blinded” or “independently and without knowledge of” are
sufficient and full details of the blinding procedure are not required.
Interpretation of the results of the reference standard may be influenced by
knowledge of the results of index test.
Patient flow
Was there an appropriate interval
between plasma and CSF Abeta
biomarker and clinical dementia
assessment?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
As we test the accuracy of the plasma and CSF Abeta biomarker for MCI
conversion to dementia, there will always be a delay between the index test
and the reference standard assessments. The time between reference
standard and index test will influence the accuracy ( Geslani 2005 ; Bourne
2007 ; Visser 2006 ), and therefore we will note time as a separate variable
(both within and between studies) and will test its influence on the diagnostic
accuracy. We have set a minimum mean time to follow-up assessment of 1
year. If more than 16% of subjects of subjects have assessment for MCI
conversion before nine months this item will score ‘no’.
Did all subjects get the same
assessment for dementia
regardless of plasma and CSF
Abeta biomarker?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
There may be scenarios where subjects who score “test positive” on index
test have a more detailed assessment. Where dementia assessment differs
between subjects this should be classified as high risk of bias.
 
Were all patients who received
plasma and CSF Abeta biomarker
assessment included in the final
analysis?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
If the number of patients enrolled differs from the number of patients
included in the 2x2 table then there is the potential for bias. If patients lost to
drop-outs differ systematically from those who remain, then estimates of test
performance may differ.
If drop outs these should be accounted for; a maximum proportion of drop
outs to remain low risk of bias has been specified as 20%
 
Were missing plasma and CSF
Abeta biomarker results or
uninterpretable plasma and CSF
Abeta biomarker results reported?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Where missing or uninterpretable results are reported, and if there is
substantial attrition (we have set an arbitrary value of 50% missing data),
this should be scored as ‘no’. If those results are not reported, this should be
scored as ‘unclear’ and authors will be contacted
Anchoring statements to assist with assessment for applicability
Question Explanation 
 
Were included patients
representative of the general
population of interest?
The included patients should match the intended population as described in the review
question. The review authors should consider population in terms of symptoms; pre-
testing; potential disease prevalence; setting 
If there is a clear ground for suspecting an unrepresentative spectrum the item should
be rated poor applicability.
Index test
Were sufficient data on plasma
and CSF Abeta biomarker
application given for the test to be
repeated in an independent study?
 
Variation in technology, test execution, and test interpretation may affect estimate of
accuracy. In addition, the background, and training/expertise of the assessor should be
reported and taken in consideration. If plasma and CSF Abeta biomarker was not
performed consistently this item should be rated poor applicability.
Reference standard
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Was clinical diagnosis of dementia
made in a manner similar to
current clinical practice?
For many reviews, inclusion criteria and assessment for risk of bias will already have
assessed the dementia diagnosis. For certain reviews an applicability statement relating
to reference standard may not be applicable. There is the possibility that a form of
dementia assessment, although valid, may diagnose a far larger proportion of subjects
with disease than usual clinical practice. In this instance the item should be rated poor
applicability.
4 Duration of conversion from MCI to Alzheimer's disease dementia
Study Duration of follow-up
< 2 years 2 years or more
Bjerke 2009   4 years (conversion within 4 years)
Bloom 2009   range: 3-12 years (mean ± SD 5.6 ± 2.7 years) for
MCI-MCI (stable); 1-8 years (mean ± SD 3.4 ± 2.1
years) for MCI-AD (converters)
Chiasserini
2010
  4 years (annual follow-up; mean follow-up not
reported)
Galluzzi 2010   mean 24.0 ± 9.7 months
Hampel 2004 mean 8.4±5.1 months (range 2-24 months); follow-up
interval for converters was 9.6±5.4,
 
Hansson 2007   mean: 5.2 years (range 4-6.8 years)
Hertze 2010   mean 4.7 years (range 3.0-7.2)
Kester 2011 median 18 months (IQR 13-24); for MCI-converters the
median was 17 months (IQR 13-24); for MCI-stable the
median was 18 months (IQR 12-25)
 
Monge-Argiles
2011
6 months (conversion within 6 months)  
Papaialgkas
2009
11 months (conversion within 11 months)  
Parnetti 12 months (conversion within 12 months)  
Shaw 2009 12 months (conversion within 12 months)  
Vos 2013   mean 2.5 years (max duration 5 years)
Zetterberg
2003
mean 20±10 months  
Graphs
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